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1. Introduction 
 
 
 
 
1.1. Antibiotics in agriculture and human diseases 
Antibiotics were first defined by Waksman more than 70 years ago as bacteriostatic, 
bactericidal and antifungal chemicals naturally synthesized by microorganisms. [1] Nowadays, 
the definition includes substances not only originated from natural products, but also those 
produced synthetically. [2] In 1946, the New York Academy of Sciences’ conference was 
focused on pharmacological properties and clinical applications of two ‘wonder drugs’: 
Alexander Fleming’s penicillin and Selman Waksman’s streptomycin. Their discovery 
revolutionized the scientific world and opened the antibiotic era in human and veterinary 
medicine giving new opportunities in the battle against pathogenic microbes. [2, 3] 
Antibiotics also play a very important role in agriculture and are widely used in livestock 
for growth control and promotion, disease prevention and treatment. [4, 5] Even though, the 
use of antibiotic growth promoters is banned in the European Union and has been relatively 
minimalized in the United States, they are still used extensively in other regions of the world. 
[6, 7]  
The ubiquity of antibiotics is the result of the worldwide increasing need for meat. 
According to statistics, the USA is the largest meat consumer over the past thirty years with 
more than 100 kg meat per capita, followed by Brazil, EU, Russia and China. During the last 
five decades in the US, the average number of chickens and cattle on the farms doubled and 
the number of pork from the animal producers more than twenty-two fold. Till now the 
biggest meat producer is China, with the amount of beef, pork and chicken almost double over 
the European production (2013), and at the same time it was estimated that half of the 
antibiotic consumption (150,000-200,000 metric tons per year) goes to livestock. In 2012, 
10,000 metric tons of antibiotics in the US and 8,000 in Europe were used in food animals. [8] 
There is a broad spectrum of antibiotics used in livestock production: tetracyclines, 
amphenicols, penicillins, cephalosporins, first-, second-, third- and fourth-generation 
cephalosporins, sulfonamides, trimethoprim, macrolides, lincosamides, aminoglycosides, 
quinolones, polymyxins, pleuromutilins and ionophores. [4, 5] Many of them are also used in 
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human medicine. [9] Moreover, up to 90% of antibiotics are already prescribed in a primary 
care, even against common, non-serious infections such as e.g. sore throat. [10, 11] According 
to statistics, 30% of antibiotic therapies are prescribed to patients inappropriately. [12] 
Consequently, the increasing usage of antimicrobials leads to the resistance of bacteria which 
has become a major threat to public health in the XXI century. 
 
 
 
1.2. Worldwide problem of antibiotic-resistance bacteria       
The resistance to critically important antibiotics for human medicine can have 
unpredictable impact on health care and clinical procedures. Antibiotic resistance has been 
associated with more frequent and longer hospitalization, longer illness, a higher risk of 
invasive infection and a twofold increase in the risk of death. [13] The main problem comprises 
drug resistant foodborne pathogens such as E.coli, Salmonella, Campylobacter, 
Staphylococcus (including MRSA - methicillin-resistant S.aureus), Enterococcus (including VRE 
- Vancomycin-Resistant Enterococcus), C.difficile, P.aeruginosa, Acinetobacter, Shigella, and 
respiratory pathogens S.pneumoniae, M.tuberculosis and K.pneumonia. [14–16] 
    According to the Centers for Disease Control and Prevention (CDC) report from 2013 
the annual number of infections in US caused by resistant  E. coli and Klebsiella was 35,300 
altogether, with 2,310 cases of death, for drug resistant Salmonella: 103,800 infected patients 
and ~40 deaths, for Campylobacter: 310,000 infections and 28 deaths, for MRSA: 80,000 
infections and 11,000 deaths; for VRE 20,000 infections, 1,300 deaths, for C.difficile 250,000 
infections and 14,000 deaths, for P.aeruginosa: 6,700 infections and 400 deaths, for 
Acinetobacter 7,300 infections and 500 deaths, for Shigella 27,000 infections and >5 deaths, 
for Streptococcus (with data regarding S.pneumoniae) 1,208,900 infections and 7,600 deaths; 
for drug resistant tuberculosis 1,042 infections and 50 deaths. [14] In Europe the situation 
does not look better. 
According to the European Centre for Disease Prevention and Control/European 
Medicines Agency (ECDC/EMEA) Joint report from 2009 at least 25,000 people die every year 
in Europe due to antibiotic-resistant infections. The estimated number of annual infections of 
resistant S.aureus (MRSA) was 171,200 with 5,400 deaths, for VRE 18,100 infections and 1,500 
deaths, for resistant S.pneumoniae 3,500 infections (data on deaths not published), for 
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resistant E.coli 32,500 infections and 5,100 deaths; for resistant K.pneumoniae 18,900 
infections and 2,900 deaths, for resistant P.aeruginosa 141,900 infections and 10,200 deaths. 
[17, 18] The annual infection and death rates coming from resistant bacteria are summarized 
in Table 1.  
 
 
 
Table.1. Annual numbers of infections and deaths caused by resistant strains of bacteria in Europe and USA, reported by 
European Centre for Disease Prevention and Control (ECDC) in 2009 and Centers for Disease Control and Prevention (CDC) in 
2013. [14, 17, 18] 
 
 
 
 
Another report of ECDC on antimicrobial resistance of Salmonella, Campylobacter, E.coli 
and S.aureus isolates from humans, animals and food published in 2013 brings bothering 
analysis. [19] 36.1% of Salmonella isolates from human were resistant to ampicillin, 35.7% to 
sulfonamides and 34.5% to tetracyclines, whereas 31.8% showed multi-resistance. Salmonella 
isolated from meat showed resistance to tetracyclines, ampicillin and sulfonamides in the 
 
Antibiotic-resistant bacteria  Annual number of infections Annual number of deaths 
C
D
C
 r
e
p
o
rt
 U
SA
 2
0
1
3
 
E.coli + Klebsiella 35300 2310 
Salmonella 103800 40 
Campylobacter 310000 28 
MRSA 80000 11000 
VRE 20000 1300 
C.difficle 250000 14000 
P.aeruginosa 6700 400 
Acinetobacter 7300 500 
Shigella 27000 5 
Streptococcus 1208900 7600 
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E.coli 32500 5100 
K.pneumoniae 18900 2900 
MRSA 171200 5400 
VRE 18100 1500 
S.pneumoniae 3500 Data not published 
P.aeruginosa 141900 10200 
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range from moderate to extremely high. Furthermore, 56% of Salmonella isolates from 
broilers were multi-resistant, as well as 37.9% from pigs and 73% from turkeys. Campylobacter 
samples from patients showed very high resistance to the clinically important antibiotics: 
more than 50% of all isolates were resistant to ciproflaxin, 33.5% isolates of C.jejuni and 58.1% 
of C.coli were resistant to tetracycline, 13.4% of C.coli isolates were resistant to erythromycin. 
C. jejuni and C. coli isolates from avian showed from high to extremely high resistance to 
ciproflaxin, nalidixic acid and tetracyclines, comparable to those from pigs and cattle. 
Percentage of resistant E.coli isolates from broilers and pigs were in the range of 6.3%-64.7% 
and 17.7%-88.0% respectively. [19] E.coli isolated from avian, pigs and cattle showed 
resistance in the range of moderate to very high to: ampicillin (13%-58.6% of isolates), 
sulfonamides (20.2%-48.6% of isolates), tetracycline (23.2%-52.8% of isolates), streptomycin 
(17.6%-50.4% of isolates) and nalidixic acid (55.4% of isolates, data referred only to broilers). 
E.isolates (E. faecium and E. faecalis) showed very high resistance to tetracyclines (from 
broilers 61.6%-87.0% of isolates, from pigs 45.6%-85.5% of isolates, from cattle 30.8%-85.5% 
of isolates) and erythromycin (from broilers 59.0%-60.6% of isolates). The resistance of 
Enterococcus to quinupristin/dalfopristin was extremely high among all types of tested 
animals, giving the number of 73.7%-94.7% of investigated isolates. Analysis of S.aureus in 
meat from turkeys, pigs, broilers and cattle was narrowed down to MRSA, and the number of 
its infection increased from 2.2% in 2009 to 20.8% in 2013. [19] The ECDC Annual 
epidemiological report from 2014 which shows that MRSA is above 25% of isolates in 7 of 29 
analyzed countries in EU/EEA. The percentage of aminoglycoside-resistant E.faecalis isolates 
is between 25%-50% among reporting countries. More than 50% of Acinetobacter spp. isolates 
were resistant to carbapenems, fluoroquinolones and aminoglycosides. Above the 10% of 
P.aeruginosa isolates in 19 of 29 reporting countries were resistant to carbapenems, and 14% 
showed multi-resistance. Resistant to both penicillin and macrolides was 10% of 
S.pneumoniae isolates within 10 from 28 reporting countries. Moreover, due to data from 
2012 in EU/EEA countries 11.9% of E.coli isolates were resistant to third-generation 
cephalosporines and 4.4% showed multi-resistance. For K.pneumonia the percentage of 
isolates resistant to third-generation cephalosporines was 25.6% and 18.2% was multi-
resistant. [18, 20] 
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1.3. From harmless bacteria to the spreading of dangerous pathogen 
Scientist, medical doctors, authorities from health organizations, all together agree that 
the resistance is a consequence of ubiquity of antibiotics in animal farming, industry and 
therefore in environment, but also because of overuse and misuse of antibiotics in human and 
veterinary medicine. [11, 13, 15, 21–23] Bacteria, which are known for their adaptive 
capabilities, have developed several mechanisms to fight against antimicrobial drugs. Even 
shortly after first uses of ampicillin in the middle of the XX century, it was noticed that bacteria 
are able to destroy its activity and survive. [3] Antibiotic resistance has its origins in gene 
mutations or in genetic elements exchange (such as plasmids, transposons, gene cassettes, 
integrons) between bacteria strains through the principle of horizontal transfer. It includes 
three mechanisms: transformation (uptake of naked DNA), conjugation (direct cell-to-cell 
transfer of genes), and transduction (bacteriophage plays the role of a DNA vector). [18, 24, 
25] Fast and direct sharing with resistant strategies is evolutionary-wise and gives bacteria an 
unquestionable advantage in the antibiotic battle. It is especially dangerous when an already 
pathogenic bacteria strain gains new resistance genes, and as a consequence can lead to the 
development of opportunistic infections not responding to current treatment (Fig.1). 
 
 
 
Fig.1. Exchange of antibiotic resistance genes between bacteria.  
 
 
Additionally, interactions between bacterial cells can lead to the development of a 
biofilm community, which structure increases the resistance to environmental stress 
influenced by antimicrobial agents. The antibiotic resistance of bacteria in a biofilm can be 
1000 times higher than in planktonic cells, what enhances the risk of failure of antibiotic 
treatment even more. [26] Resistance can be spread easily in many different routes, linking 
human population with agriculture. The net of correlations is shown in Fig.2. 
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. 
Fig.2. Scheme describing the spread of antibiotic resistance. [18] Antibiotic resistance can be the result of two 
processes: 1) genetic changes of bacteria caused by uptake of gene elements or mutations, 2) natural selection 
after contact with antibiotics. Resistance can be easily spread bewteen human, environment, agriculture and 
livestock. 
 
 
 
 
 
Animals, humans, agriculture products and environment (soil) are possible sources of 
resistant pathogens. Bacteria can be transferred between all of them through contaminated 
vegetables, meat, sewage, manure or by direct contact with infected animals or people. [15, 
25, 27, 28] Therefore, farms and hospitals should be considered as places of increased risk. 
Due to the effect of ‘global village’ and rising number of travelers, the epidemiology of 
antibiotic-resistance can get out of control by dissemination across the borders. [18, 29, 30] 
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1.4. Mechanism of antibiotic resistance 
Different molecular mechanisms of resistance are described: antibiotic target 
modification, compound chemical modification, active efflux or molecular bypass.[31] The 
first option is based either on genetic point mutations (e.g. mutation in DNA gyrase leads to 
resistance to synthetic fluoroquinolone antibiotics - ciprofloxacin) or efficient and selective 
enzymatic activity within microorganisms (e.g. in ribosome methyltransferases). The result in 
both cases is a special conformation change in the bacterial target of the drug – as a 
consequence antibiotic cannot bind and loses efficiency of its molecular strategy of action. 
The same happens in so called molecular bypass. This is a process of replacement of antibiotic 
sensitive molecular targets by neutral ones, for example vancomycin resistance is a result of 
replacement of an amide with an ester. Another example is chemical modification, where 
antibiotics are inactivated by enzymatic catalysis (e.g. ß-lactamases destroy ß-lactams by 
hydrolyzing their four-atom ring). While the mechanism of efflux pump, supported by 
membrane proteins, helps bacteria actively remove antibiotics extracellularly. [18, 26, 31] 
Further chapters are focused on the strategy based on antibiotic-degrading enzymes – ß-
lactamase mediated resistance. All the mechanisms described above are showed 
schematically on the Fig. 3. 
 
 
 
Fig.3. There are different molecular mechanisms involved in antibiotic resistance: a) inactivation of antibiotic by 
enzymatic catalysis, b) elimination of antibiotic by active efflux, c) molecular change of the target so antibiotic 
cannot bind.  
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1.5. Beta lactamases 
While in 1940s the world seemed to have found a gold remedy against bacterial 
infections - penicillin, Abraham et al. soon reported mechanism of its inactivation by ß-
lactamase. [32] Beta lactams are the biggest group of antibiotics, which mechanism of action 
blocks the synthesis of the bacterial cell wall. During the cell wall synthesis, single building 
blocks of peptidoglycan (murein) are crossed-linked by D-Ala-D-Ala carboxypeptidase. Four-
atom ring of beta-lactam antibiotics perfectly mimic the structure of D-Ala-D-Ala residue and 
competitively inactivate the catalytic site of peptidase, so the peptidoglycan polymer cannot 
be formed. As a consequence bacteria undergo osmotic instability and die. Bacterial enzymes 
called ß-lactamases, hydrolase ß-lactam ring of antibiotics and destroy their antibacterial 
properties. In the 1960s, the first ß-lactamase was described – TEM-1 was synthesised by E.coli 
strain isolated from a Greek patient Temoniera, after whom the enzyme was named. [33] 
Shortly after, different ß-lactamases were detected in other family members of 
Enterobacteriaceae, as well as in K.pneumoniae, P.aeruginosa or A.baumanii worldwide, 
showing resistance activity against growing group of ß-lactam antibiotics. Until now 1,886 
different ß-lactamases were identified. [34–37] ß-lactam resistance genes can be encoded on 
chromosomes or on plasmids, in both gram negative and gram positive bacteria. [38, 39] In 
gram positive bacteria, ß-lactamases are synthesised extracellularly, in gram negative 
cumulate in the periplasmic space. There are two schemes of ß-lactamase classification and 
they are based on differences in: functionality – Bush-Jacoby-Medeiros, and structure (protein 
sequence) – Ambler. [35, 36, 39] Even though functional classification provides selective ß-
lactams resistance profiles, the structural scheme is easier to analyse and less controversial, 
considering such a huge diverse group of enzymes. Based on differences in amino acids 
sequences, Ambler proposed 4 classes of ß-lactamases: A,B,C and D. [36, 39, 40] A diagram of 
the sequence similarity network between ß-lactamases variants is shown on Fig. 4. [37] In the 
classes A,C and D the mechanism of ß-lactam ring hydrolysis is active Serine-based, class B is 
a group of metallo-ß-lactamases which require a Zink ion for this reaction. Classes A, C and D 
share a similar motif of amino acids including presence of Serine and Lysine residues in the 
active site, which is situated between two domains α and α/ß. Examples of ß-lactamases from 
classes A, C and D are depicted in Fig.5. [40]  
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Fig.4. ß-lactamase sequence similarity network based on 1,494 variants. Behind each dot stands a unique amino 
acid sequence.[37]  
 
 
 
 
Fig.5. Structure and function of A, C and D class ß-lactamases show many similarities. Three representatives are 
presented: a) class A- TEM-1, b) class C- CMY-2, c) class D- OXA-10. ß-sheets are green-, α-helixes blue- and loops 
gray-coloured. In all these classes the active site contains Serine and Lysine residue necessary for the mechanism 
of hydrolysis of the ß-lactam amid bond (d). [40] 
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Moreover, the sequence and 3D structure homology suggest that class A and C might 
have evolved from the same origin. [41–45] Most of ß-lactamases which became clinically 
relevant are those plasmid-encoded, synthesised in gram negative bacteria and mainly 
incorporated into class A. Molecular class A (functional group 2) is also the one which grew 
the most last years with the highest number of newly reported naturally occurred enzymes 
(Fig. 6). [46]  
 
Fig.6. Number of newly reported naturally occurring ß-lactamases from different classes (functional/molecular) 
over the years. Among all the classified ß-lactamases, the group 2/class A was the one which expanded the most. 
Figure adapted from American Society for Microbiology, 2010 by Bush et al. [46] 
 
 
 
1.6. Class A ß-lactamases  
Class A is a group of broad spectrum ß-lactamases hydrolyzing penicillins, 
cephalosporines, in some cases monobactams and carbapenems. [35] This group is mostly 
represented by TEM and SHV types, with parental enzymes TEM-1 and SHV-1 sharing 68% 
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sequence homology. Another fast growing type is CTX-M but it stands phylogenetically further 
from TEM and SHV. [46, 47] This class is clinically important as it is a source of Extended 
Spectrum ß-lactamase mutants (shown in Fig. 7). [37]  
 
Fig.7.Phylogenetic tree of 1,886 ß-lactamases. Different Ambler’s classes are colored in: grey- A, light blue- B1, 
dark blue- B2, purple-B3, green- C, D-red. CA stands for Clavulanic acid, TZB- tazobactam. Diagram indicates that 
class A is the source of ESBLs.[37]  
 
 
 
Based on crystallographic structure analysis of these enzymes, two domains can be 
distinguished: α (with 8 α-helixes) and α/ß (with 3 α-helixes and 5 ß-strands). [42, 48] The 
active site is placed between these two domains, and contains highly conserved residues: 
Ser70, Ser130, Lys73, and Lys234 which take part in the process of ß-lactams hydrolysis. [49, 
50] The important structure is the Ω-loop which is placed between amino acid number 161 
and 179 and hangs above the active pocket. It contains another two conserved residues Glu 
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166 and Asn 170 important for catalytic function of the enzyme. [40, 47, 50, 51] The active site 
based on crystal structure of TEM-1 and SHV-1 can be viewed in Fig. 8.  
 
 
 
 
Fig.8. Conservative residues in the active site of A class ß-lactamases. Asn170 and Glu166 are situated on the Ω-
loop which creates a rim over active pocket with residues: Ser70, Lys73, Ser130 and Lys 234. Structure was 
created with the Chimera program, based on crystal structures of TEM-1 and SHV-1 (Pdb: 1axb and 1shv).  [52] 
 
 
 
 
For the whole A-class of ß-lactamases the reaction of hydrolysis of ß-lactams is a cycle 
process based on two processes: acylation and deacylation, where the main role is played by 
Ser70 attacking the ß-lactam carbonyl of the antibiotic. [53, 54] Acylation is the reaction of 
creating an acyl group on another chemical compound through the reaction with a hydroxyl 
group. In this situation the hydroxyl group carrier is amino acid residue Ser70 from ß-
lactamase. A non-covalent enzyme-substrate complex (Henri-Michaelis complex) formation is 
the first step of the acylation reaction (Fig. 9). [55] A nucleophilic attack on the ß-lactam 
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carbonyl by the hydroxyl group of Serine is catalyzed by the presence of a general base (this 
can be either Glu166 or Lys73). [56, 57] Two mechanisms are likely possible: a proton is 
transferred to Lys73 directly or via hydrolytic water positioned and coordinated by Glu166, 
Asn170 and Ser70. [50] In the next step, an oxygen from Ser70 residue is ready to attack a 
carbonyl carbon of the ß-lactam ring, what proceeds through the formation of a tetrahedral 
intermediate. It is also proposed that meanwhile the Lys73, Ser130 and Lys234 residues take 
part in the protonation of a nitrogen from the ß-lactam ring. [57–61] Consequently, an amid 
bond breaks and a acyl-enzyme adduct is formed. Next, the hydrolytic water molecule is 
activated by a general base Glu166, attacks the acyl-enzyme adduct and as a result a 
tetrahedral intermediate is formed. [58, 62] Lys234 is proposed as a stabilizing residue for this 
structure. [55] Then, as a consequence of deacylation, the ß-lactam ring of antibiotic is 
hydrolyzed and the tetrahedral intermediate turns into an enzyme-product complex. Beta 
lactam loses its primary activity due to the conformation changes. [42, 58] The scheme of 
acylation and deacylation process is shown on Fig. 10.  
 
 
 
Fig. 9.  Henri-Michaelis complex of ß-lactam antibiotic and A-class ß-lactamase.[55]  
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Fig.10. The hydrolysis of ß-lactams by A class ß-lactamases is a cyclic process based on two processes: acylation 
and deacylation. After the formation of a non-covalent enzyme-substrate complex, in the presence of a general 
basis, Ser70 residue attacks the amid bond of ß-lactam. Through the acylation reaction an acyl-enzyme adduct is 
formed. Due to the hydrolytic water activation, the acyl-enzyme adduct undergoes a deacylation reaction and 
turns into an enzyme-product complex. As a result, the amid bond of ß-lactam is hydrolyzed and loses its 
functionality, and ß-lactamase is regenerated ready for another reaction cycle. [57]  
 
 
 
1.7. TEM-1 and ESBLs 
TEM-1 is a plasmid encoded, 29 kDa atomic mass enzyme, representing the predominant 
group of TEM type ß-lactamases providing antibiotic resistance within the Enterobacteriaceae 
family. Its hydrolytic profile indicates activity against penicillins, first generation 
cephalosporins – cephaloridine, cefazolin, second generation cephalosporins - cephalotin, but 
not against the third generation of cephalosporins (cefotaxime, ceftazidime) and monobactam 
aztreonam, and it is inhibited by clavulanic acid (CLA) and tazobactam (TZB). [46, 63] Like it is 
mentioned in chapter above, TEM-1 as a member of class A enzymes,  has two domains α and 
α/β, with the active site placed between them. Two of the most important and conserved 
catalytic residues Lys73 and Ser70 are located on the helix H2. Together with Glu166 and 
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catalytic water molecule participate in acylation step in reaction of the ß-lactam hydrolysis. 
[59, 64] 
Other important non-mutable residues are situated in a Ω-loop: Glu166 and Asn170. 
Asn170 helps in positioning the catalytic water molecule by forming the hydrogen bond 
through the side chain of the residue. Then, it enables the Glu166 to activate the water 
molecule in the deacylation step. [42, 58, 65–68] A visualization of ß-lactamase TEM-1 can be 
found in Fig.11. 
  
 
 
Fig.11. Visualization of ß-lactamase TEM-1. A, B - 3D Crystal structure of a phosphonate- TEM-1 complex 
visualized in the Chimera. Phosphonate belongs to the structure of inhibitor used in this crystallographic study. 
[52, 69] C – cartoon picture of TEM-1 with active site in the black square. D- conserved amino acid residues of 
active site including these responsible for positioning of the catalytic water, colored in grey.PDB 1BTL.[50]  
 
 
 
The Ω-loop forms a rim over the active pocket of TEM-1 and it has a huge impact on the 
structure and function of the enzyme. It is directly involved in substrate interaction, water 
A B 
C D 
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coordination necessary for catalysis, and is mutation-sensitive. [58, 70, 71] B-lactamases are 
highly mutable enzymes, single substitutions of amino acids can change their interaction with 
a substrate, leading to the development of new mutants with an enlarged antibiotic hydrolysis 
profile - so called Extended Spectrum Beta Lactamases (ESBLs). Apart from possessing a 
standard ß-lactamase functionality, they are able to hydrolyze the third generation of 
cephalosporins and aztreonam. These TEM-type derivates have been developed as a 
consequence of mutations in blaTEM-1 gene resulting in amino acids substitutions, which mainly 
occur within or near the active site, alone or combined and mostly appear as follow: 
Glu104→Lys, Arg164→Ser/His, Gly238→Ser, Glu240→Lys. [72, 73] Some examples of TEM-1 
mutants with ESBL profile are shown in Fig. 12. 
 
  
Fig.12. TEM-type ESBL derivatives. Examples of amino acid substitutions which provide the ESBL 
phenotype in newly developed TEM ß-lactamases in comparison to TEM-1 sequence marked in gray. TEM-2 does 
not have a ESBL hydrolysis profile but was included in the figure as a TEM-1 derivate. [73]  
 
 
 
 
 
These amino acids mutations can change the flexibility of the Ω-loop, the size of a space 
around the active pocket where the substrate is bound or stabilize the conformation of the 
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enzyme. [63, 66] These changes enable ESBLs to hydrolyze new generations of antibiotics. As 
an example of a TEM-1 mutant can be a clinically found ESBL TEM-52, which is able to 
hydrolyze additionally the third generation cephalosporin (cefotaxime). Even though 
mutations did not cover the active site residues of the enzyme, the set of important functional 
substitutions E104K/G238S/M182T changed the conformation of the loops near the active 
site. [74] It resulted in the change of the pI value for TEM-52 and its kinetic parameters in the 
interaction with penicillins, first- and third- generation of cephalosporines. (shown in Tab. 2. 
and 3.)  
 
 
 
Tab.2. Comparison of amino acid residues at critical positions and isoelecric point (pI) values between 
TEM-1 and TEM-52. [75] 
 
ß-lactamase pI aa substitution Ref. 
104 182 238 
TEM-1 5.4 Glu Met Gly [76] 
TEM-52 6.0 Lys Thr Ser [75] 
 
 
Tab.3. Comparison of Michaelis constant values (Km) between TEM-1 and TEM-52. TEM-52 shows smaller 
values of Km in reaction with penicillins and I-generation of cephalosporins, this means the affinity between 
substrate and enzyme is stronger than with TEM-1, and as a result the efficiency of antibiotic hydrolysis is higher. 
Moreover TEM-52 as a ESBL hydrolyses III-gen cephalosporins, while the Km of TEM-1 ß-lactamase in reaction 
with this group of antibiotics could not be determined.  [75]  
 
                        substrate Km (µM) 
TEM-1 TEM-52 
penicillins Benzylpenicillin 26 5.3 
Ampicillin 40 4.1 
I-gen. 
cephalosporines 
Cefaloridine 244 13 
 
III-gen  
cephalosporines 
Ceftazidime - 239 
Cefotaxime - 30 
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 There are two almost opposite hypotheses explaining how the E104K/G238S 
substitutions influence the TEM-52 ability to hydrolyze cefotaxime. It depends on the type of 
the study – crystallography or new drug design technique called Boltzmann docking. 
Importantly, in comparison to previous generations of cephalosporins, the third generation 
has a bulkier structure. The theory based on crystallographic models proposes that these 
amino acid substitutions open up the active site via motion of the loop between residues 238 
and 242. It enables the enzyme to bind larger substrates and as a result to hydrolyze them. 
[77, 78] The hypothesis built on molecular dynamics simulations and Markov state models, 
which are the base of the Boltzmann docking approach, says that E104K/G238S substitutions 
do not change the conformation of the 238-loop but decrease the flexibility of the Ω-loop and 
pins it down towards the active pocket. This conformational change, together with the change 
in charge, promotes the heterogenicity in a substrate binding and enhances the hydrolysis 
rate. [74] Additionally, the mutation M182T stabilizes TEM-52 by suppressing aggregation and 
misfolding of protein caused by other substitutions. [79] 
This mechanism shows how efficiently ß-lactamases can provide the resistance to newly 
introduced antibiotics through fast genetical evolution. The outbreak of ESBLs can be 
explained by selective pressure coming from the mass scale introduction of aminopenicillins, 
III-generation of cephalosporin and aztreonam. [46, 80] On the other hand, it can be 
supported by naturally occurred mutants, which exchange resistance encoded genes with 
clinical strains. Due to the fact that penicillins and cephalosporins have their origin in 
microbiological organisms, resistance against them could have been developed by bacteria in 
parallel. Nowadays more than 200 TEM type variants were identified and   8̴6 of them have 
ESBL phenotype. [36, 70, 81]  
 
 
 
1.8. ESBLs in negative gram bacteria 
In 2017, the WHO published a report entitled “The global priority list of antibiotic 
resistance bacteria to guide research, discovery and development of new antibiotics” grouping 
pathogens according to the level of their resistance: critical, high and medium. [82] The critical 
group encompasses extended spectrum beta lactamase producing Enterobacteriaceae. ESBLs 
are strongly related to Gama Proteobacteria class, especially to Enterobacteriaceae family 
including species such a E.coli and Klebsiella. [37] These gram negative bacteria differ from 
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gram positive species in cell wall structure morphology. The cell wall of gram negative bacteria 
consists of a thin layer of peptidoglycan polymers outstretched in the periplasmic space, which 
is closed by a cell membrane and an outer membrane. The outer membrane contains in its 
structure porins transporting sugars, ions and amino acids, efflux pumps moving toxic 
substances and antibiotics out of cells, and lipopolysaccharides which determine endotoxin 
properties. [83] Among gram negative bacteria, the mostly identified types of ESBLs are 
TEM/SHV or CTX-M, which are synthesized constitutively and secreted in the periplasmic 
space. These enzymes are reported worldwide in clinical isolates. [36, 84–93]  
Enterobacteriaceae can be common human commensals. Although, E.coli and Klebsiella 
are present in healthy individuals e.g. in gastrointestinal tract or genitourinary tract, 
pathogenic strains, especially these producing ESBLs, can cause serious clinical diseases like 
intra-abdominal abscess, cholangitis, gastroenteritis, peritonitis or infections of urinary tract 
and severe diarrhea  (mostly in developing countries).  [91, 94–96] 
Moreover, the gastrointestinal tract is considered as a reservoir of resistant 
Enterobacteriaceae and as the environment which favors the transmission of antibiotic 
resistant genes between microorganisms. [97–101] Additionally, the uses of new generation 
antibiotics e.g. cephalosporines can also, as a side effect, support the growth of new ESBL 
mutants. By eliminating a treatment-sensitive bacteria (not only pathogens but also good 
flora), the gastrointestinal environment becomes less nutrition-competent, hence, favors the 
colonization of new ESBL producing Enterobacteriaceae. This phenomenon is called the 
selective pressure and it is one of the explanations why it is so difficult to find a long-term 
effective antibiotic. [97] This is a serious threat for patients suffering from diseases that 
diminish the organism’s condition and immune system, and require long hospitalization. [91, 
102–104] 
There are several guidelines for the antibiotic treatment against ESBL-associated 
bacterial infections, although the options get narrowed down fast due to the limitations of the 
pharma industry and the speed of new resistant strains development. [105–107]  ESBLs are 
already resistant to almost all ß-lactam antibiotics, with exception to cephamycins and some 
carbapenems. Additionally, plasmids encoding ESBLs, very often also contain other antibiotic 
resistant genes. Moreover, the medical history of a patient has the biggest influence on the 
effectivity of chosen therapy: past treatments with antibiotics, implants or prosthetic devices, 
and also metabolic diseases. [108, 109] 
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Recommended antibiotics against gram negative ESBL-producing bacteria include: 
colistin, fosfomycin and temocillin. An alternative option is the bacteriostatic drug – 
tigecycline. There are also strategies combining two compounds, such as: a dual-carbapenem 
therapy, a new generation cephalosporine + ß-lactam inhibitor (e.g. Ceftolozane/tazobactam) 
or a III-generation cephalosporin + non-ß-lactam inhibitor (e.g. Ceftazidime/avibactam). [106] 
Unfortunately, all of these treatments are not always the final remedy for infection and 
additionally, can cause side effects such as nausea, diarrhea, headache, and fever or promote 
further resistance development. That is why scientist place great hopes on prophylactics and 
alternative treatment strategies. One of these is a strategy based on antibodies, using its 
natural potential of binding and inactivating toxic substances and pathogenic microorganisms.  
 
 
 
1.9.  Concept of passive immunotherapeutics 
    Passive immunization is a concept of administering specific antibodies obtained from 
a donor or developed commercially, to a patient or animal, as a prophylaxis or therapy. 
Naturally occurring examples of this process are: transfer of immunity from a mother to a child 
in milk and transfer of IgY antibodies from a hen to egg yolk of offspring, in mammals and 
avian, respectively. The first use of passive immune properties, dates back to end of the XIX 
century, when Emil von Behring treated diphtheria and tetanus with rabbit serum therapy. He 
received the Nobel Prize in Physiology and Medicine for this in 1901. [110] Next decades 
serum therapy was clinically used against pneumococcal pneumonia, scarlet fever and 
meningitis until the newly discovered antibiotics replaced them. [111] The interest in passive 
therapy has returned though, with the growing problem of antibiotic-resistant bacteria. It 
mainly refers to the introduction of specific mammal-origin Immunoglobulin G, what can 
provide short-termed but straightaway protection or neutralize pathogenic units (e.g. 
bacteria, viruses, toxins). There are already some licensed medical products based on 
polyclonal antibodies against infectious diseases such as: C.botulinum toxin, Cytomegalovirus, 
Hepatitis A and B, Rabies, Measles, Tetanus, Vaccinia, Varicella Zoster. [112] Also, due to 
hybridoma technique of producing monoclonal antibodies, passive immune therapies has 
started to develop in the field of cancer, immune diseases and allergy. [112–114] 
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 Unfortunately, the limits of this approach are still: high costs, small quantities of 
antibodies and ethical concerns regarding welfare of animals. In the last two decades, a great 
interest in IgY technology has been observed. IgY antibodies can be produced against many 
different antigens including pathogens, that is why they can be used as a specific 
immunotherapeutic agent against bacteria, e.g. as a complement or replacement of 
antibiotics. This is a very attractive approach especially because of the emerging antibiotic 
resistant microorganisms. Passively administrated antibodies can provide rapid and fast 
protection against diseases unresponsive to antibiotic therapies or for patients with immune 
system defections who are not able to use conventional treatment or vaccinations. 
 
 
 
1.10. Immunoglobulin Y: characteristics and function 
    IgY antibodies are polyclonal immunoglobulins produced by avian species against 
pathogens, in order to provide an immunogenic response in newly hatched chicks, in which 
humoral immunity is still not developed. They are present mostly in serum and egg yolk, which 
provides nutrition to embryos, and are also the dominant class of immunoglobulin in aves. 
[115, 116]  As a member of Vertebrates, the avian immune system is based on two types: 
innate and adaptive. The second latter is highly specific to pathogens and can be further 
divided into cellular and non-cellular response. They are carried by two types of cells: B and T 
lymphocytes, respectively. In the cellular response, T cells control the activity of macrophages, 
T-helpers and B-cells against the antigen recognized as pathogenic. In non-cellular response, 
also called humoral, B-cells produce antibodies which circulate in blood and plasma, and can 
protect organism from pathogen by: agglutination, activating opsonization, activation of cell-
mediate cytotoxity or neutralization. B-cells are produced in yolk sack, bone marrow and 
embryonic liver, and mature in the Bursa of Fabricius, a very unique primary avian lymphoid 
organ. When B-cells are fully developed, they migrate with the blood to the spleen, tonsils, 
bone-marrow, thymus and Harderian gland. B-cells activated by T-helper cells turn into 
plasmocytes and secrete highly antigen-specific immunoglobulins. [117–119] High 
adaptability and diversity of immunoglobulins in birds is provided by gene hyper conversion, 
V-J flexible joining and somatic point mutations, as in mammals, but with some differences. In 
avian antibodies, the heavy and light chain loci possess only one functional V gene, and, 
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additionally, a family of 25 pseudo-V genes without a transcriptional and recognition signal. 
At the beginning of a bird life, in process of gene conversion, base pairs from pseudo V-genes 
replace homologues sequences in functional V gene. As a result, the immune system can 
generate a huge repertoire of different immunoglobulins. This process occurs around two 
weeks after the B-cells are transferred to the Bursa of Fabricius to become mature. When a 
bird is older diversification of immunoglobulins is maintained by somatic hypermutation. [116, 
120]  
 Three classes of immunoglobulins in birds are known: IgY, IgM and IgA. When the egg 
is being formed, developed IgYs are transfered with the mother’s blood to the egg yolk. It 
proceeds by a FcRY-receptor-dependent transport from the yolk sac membrane through the 
yolk and further to the blood of the embryo. This transport is also pH-dependent. At pH 6, IgYs 
are bound by FcRY receptors in the egg yolk when they trans-pass the membrane. These 
complexes release IgYs when they reach the blood, where pH is 8. [121, 122] At the later stages 
of egg development, other types of antibodies such as IgMs and IgAs are transferred from the 
oviduct and deposited into the egg white. [123] Fig. 13 shows a schematic picture of different 
avian immunoglobulins.  
 
Fig. 13. A scheme of avian immunoglobulins distribution during egg development. [123]  
 
 
 
At the beginning, IgYs have been called as IgGs, due to similarities in their function and 
origin (IgY is a progenitor of IgG). It has changed due to Leslie and Clem et al. in 1969 who 
differentiated IgYs from IgGs. [115] Differences in their molecular structure and properties can 
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be clearly seen e.g. IgYs do not contain a well-defined hinge region, possesses four constant 
domains (instead of three like in IgGs) in addition to the variable domain, IgYs are more 
hydrophobic because of their bigger hydrophobic Fc region, their isoelectric point is between 
5.7 and 7.6 (for IgG 6.1-8.5) and it has bigger weight (IgY ~180 kDa, IgG ~160 kDa). There are 
also differences in biological functions: compared to IgGs, IgYs do not provoke the mammalian 
complement system, do not interact with mammalian Fc receptors, do not bind to rheumatoid 
factor, neither to protein A nor G. [116, 119, 124–126] Fig. 14 shows the differences between 
an IgG and an  IgY.  
 
 
 
 
Fig. 14.  A scheme of an IgY and an IgG showing the main structural differences. [119] 
 
 
 
1.11. IgY technology  
    IgY technology is the production of specific polyclonal antibodies in birds (mostly in 
chickens), using their natural way of maternal passive immunity transition to offspring. This 
approach is relatively cheap, effective, simple and more ethical than using mammalian system. 
It is officially recognized as the alternative method for antibody production supporting the 
animal welfare. [127] IgYs are widely used in commercial and research applications, including 
the fields of diagnostic and proteomics. [128] Although the most valuable and promising IgY 
 38 Development of candidate IgY antibodies against ESBL-producing gram-negative bacteria for oral therapy 
application is to use it to treat and prevent human and animal diseases. [123] The first step 
includes the immunization of chickens with chosen antigens. The IgYs produced as a response, 
are transported with the blood to the egg and accumulate in egg yolk in high quantities. As a 
next step, IgYs are purified and can then be administrated orally to the host organism/ patient, 
where they can function as an acquired passive immunity against the specific pathogen their 
development was based on. The whole process of IgY production takes 4-8 weeks. The entire 
procedure is shown in Fig.15.  
 
 
 
 
Fig.15. Development of specific IgYs in chickens consist of several stages: 1) identification of antigen 
(pathogen), 2) immunization with antigen in several cycles to increase the final concentration of IgYs, 3) 
development of IgYs and transfer to egg yolk, 4) purification of IgYs from other egg components, 5) final batch of 
specific to antigen IgYs. [18] 
 
 
 
There are many advantages of using avian IgY antibodies: 1) easy purification (only one 
class of IgY antibodies in egg yolk and high IgY concentration), 2) polyclonal, so its specificity 
to antigen will not decrease significantly after the change of single epitopes, 3) can be 
produced against conserved mammalian proteins, 4) do not recognize mammalian epitopes, 
5) method of production is not harmful to animals (collecting eggs instead of blood), 6) can be 
used in passive immunization. [119, 123, 129, 130] IgYs are accumulated in egg yolk in high 
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doses - 1 ml contains up to 25mg of IgYs.  Additionally, IgYs show high stability at temperatures 
ranging between 30 – 70 °C, and in pH 3.5 – 11. [18, 129]  
Chicken are immunized with the antigen of interest in the dose between 10µg and 1mg, 
starting usually with the initial immunization followed by three booster doses in time intervals 
to obtain higher antibody titers. There are different methods of an antigen introduction: 
subcutaneous, intramuscular, intravenous or oral. Intravenous rout can cause anaphylactic 
reaction, has to be introduced very slowly and should be used without adjuvants. Among all 
the methods, the highest antibody titers are achieved by intramuscular injections. [118, 131–
133] First specific IgYs can be already found in serum after 6-7 days. [134] 
An optimal dose of antigen depends on its size and type and has to be experimentally 
tested. For example it is advised to use carriers e.g. BSA or KLH to couple small antigens like 
short peptides below 10kDa, to enhance the immune response. When immunization is done 
with an antigen bigger than 50kDa, obtaining 2-10% specific activity of IgYs can be expected. 
Unfortunately, a drop down of specificity to less than 1% can be observed, when antigen has 
lower molecular weight. [116] 
Additionally to antigen, modulators stimulating B-cells can be used, which improve the 
immune response in chickens e.g. Freund´s complete adjuvant- mycobacterial antigens 
emulsified in mineral oil (FCA), Freund´s incomplete adjuvant – water and oil emulsion (FIA), 
specol – water with purified mineral oil or lipopeptide Pam3Cys-Ser-(Lys)4 (PCSL). FCA is the 
most popular and most effective one. [116, 135, 136]  
One hen is able to produce up to 150mg IgYs per egg. When this number is combined 
with average number of eggs hen can lay per year – 325, it can give a result of 40g of IgYs per 
year. When compare with mammals- 200mg of IgGs per bleed giving 1.4g of antibodies per 
year. [130, 137–139] A comparison between production of polyclonal antibodies in chickens 
and mammal is shown in Table 4.  
There are different methods of IgY purification depends on scale, costs, effectiveness 
and technology: 1) precipitation with e.g. salt, dextran/sodium/ammonium sulphate, xanthan, 
ethanol, polyethylene glycol (PEG), 2) chromatography and 3) ultrafiltration. All these 
methods are summarized in Schade et al. 2005. [116] Usually, in order to obtain higher purity 
or ratio of specific IgYs, methods are mixed e.g. precipitation is followed by affinity 
chromatography. 
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Tab. 4.[130]  
 
 
 
 
1.12. IgYs against pathogenic bacteria  
The choice of an antigen depends on the characteristics of the pathogen and therapy 
strategy. IgYs can be generated against colonization factors (outer membrane proteins, 
fimbriae/pili and lipopolysaccharides), flagella, mucosal receptors, enzymes and toxins 
important for bacterial survival. [140, 141] Wherefore, several strategies for using IgYs in host 
protection can be distinguished: 1) agglutination of bacteria, 2) inhibition of bacterial 
adhesion, 3) suppression of virulence factors, 4) toxin neutralization and, 5) enzyme 
inactivation. [142] They are shown on Fig. 16. The process of chicken immunization can be 
influenced by the following factors: antigenicity of the immunogen, type of adjuvant, route of 
antigen delivery, frequency of administration, avian properties (breed, age, egg lying 
capacity). [116] 
IgY technology is an effective way to provide immunity against a wide range of 
pathogens, which can reduce or possibly replace the use of antibiotics in clinics and industry, 
and provide successful prevention, treatment, or growth enhancement overtaking the 
problem of increasing antibiotic resistance. An increased number of reported IgYs against a 
wide range of bacteria can be observed. Generated IgYs against anti-cell-associated 
glucosyltransferase (anti-CA-GTAase) of S.mutans can selectively suppress oral colonization of 
those microbes. [143–145] Specific IgYs inhibit the adherence of S.mutans by 59%, but only 
8% when IgYs from non-immunized hens were used, which shows that anti S.mutans IgYs 
could be used to prevent dental plaque in humans. [145] Anti-P.gingivalis-IgYs can be used as 
prevention for periodontitis.[146] In vitro studies on human intestinal epithelial cell culture 
Parameter Mammal IgG Chicken IgY 
Source of antibody Blood serum Egg yolk 
Antibody sampling Bleeding (invasive) Collecting eggs (non-invasive) 
Antibody amount 200mg/bleed (40 ml blood) 100-150mg/egg (5-7 eggs per 
week 
Amount of antibody per year 1,400mg 40,000mg 
Amount of specific antibody ~5% 2-10% 
 41 Introduction 
Caco-2, show that S.enteritidis incubated with specific IgYs, lose their adherence to human 
cells what inhibits the bacterial infection. [18, 147] 
 
 
 
 
Fig.16. Four different strategies to target pathogenic bacteria with IgYs. [18] Immunoglobulins Y can be 
developed against enzymes/toxins expressed by bacteria and neutralize them by blocking their active site or 
building a kind of coat all over their surface. IgYs can also target microbes directly by blocking their 
adhesion/virulence molecules or coat their surface what suppresess the biological functions of bacteria.  
 
 
 
 
Nilsson et al. made a 12 year study on prophylactic oral IgY treatment against 
P.aeruginosa on 17 patients and reported in most cases prevention of its colonization, which 
indicates the high potential of IgYs as a prevention for respiratory infections caused by this 
bacteria. [148] Therapeutic strategies based on IgYs, generated against bacterial 
enzymes/toxins also bring promising results. LeClaire et al. and Trott et al. reported that IgYs 
specific to enterotoxin B and botulinum type A, neutralize their activity and therefore can 
prevent and treat infections of Staphylococcus aureus and Clostridium spp., respectively. [149, 
150] Hirai et al. passively immunized mice with 3 different types of IgYs specific to V.cholerae: 
anti-01, O139 and anti-cholera toxin B and reported effective prevention of cholera infection. 
[151] Another example is anti-UreC-IgY, which was generated against one of the subunits of 
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Urease enzyme and successfully prevented and eradicated antibiotic resistant H.pylori 
infections causing gastritis, gastric ulcer and gastric cancer. [140, 152] Added as a supplement 
to food, for example in yogurt, IgYs can be used as a widely available prevention and treatment 
for humans and animals against H.pylori. [153, 154] IgYs against E.coli 0157:H7 also have high 
potential to be a food additive for passive immunization protecting humans from harmful 
results of its infections: diarrhea, hemorrhagic colitis and hemolytic uremic syndrome.[155]  
    IgYs can be used as well in farm animals for prevention and as an alternative treatment 
in the form of a food additive against common bacterial livestock diseases. Li et al. reported 
Anti-K88+ IgYs successfully prevented E.coli infection in pigs. [156] The growth of E.coli in 
cattle was inhibited by Anti-O111 IgYs and increased uptake by macrophages was observed. 
[157] Yokoyama et al. orally administrated specific IgYs against S.typhimurium and S.dublin to 
neonatal calves, which prevented salmonellosis in animals. [158] Gurtler et al. reduced 
salmonellosis of eggs from previously infected chickens by oral therapy with anti-S.enteritidis-
IgYs. [159] Moreover, Zhen et al. studied the efficacy of IgYs against bovine mastitis caused by 
S.aureus and compared it with antibiotic therapy and reported that usage of IgYs for clinical 
and experimental bovine mastitis showed cure rates of 50% and 83.3%, respectively. In 
comparison to penicillin the cure rates were 33.3% and 66.7%, respectively. [160] Another 
example is research done by Tsubokura et al. on IgYs against C.jejuni as a prevention and 
therapy for infected chickens. Prophylactic efficacy was observed as a 99% decrease of 
number of bacteria, and therapeutic efficacy as an 80-95% decrease number of faecal bacterial 
counts. [18, 161] IgYs generated against different bacterial strains are summarized in Table 5.  
 
 
 
 
 
Tab. 5. Examples of IgYs generated against different antibiotic resistant bacterial strains. [18] 
Pathogen Target IgY therapy        
Reference 
Streptococcus 
mutans 
humans Inhibition of bacterial adherence and 
prevention of dental plaque 
[145] 
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Helicobacter pylori humans Anti-UreC-IgYs inactivate Urease and 
eradicate H.pylori colonization 
[140] 
Escherichia coli humans IgY Inhibits the growth of  E.coli O157:H7 
strain  
[155] 
pigs Anti-K88+-IgYs protect against E.coli and 
enhance weight 
[156] 
cattle Anti-O111-IgYs inhibit growth of E.coli 
and activate uptake by macrophages 
 
[157] 
Salmonella spp.  Cattle  IgY against S. typhimurium and S. Dublin 
protects neonatal calves from infection 
and lethal effect  
[158] 
humans IgYs generated against Salmonella 
Enteritidis protects infected cultured 
human intestinal epithelial cells by 
inhibiting the bacterial adhesion 
[147] 
chickens Anti-Salmonella Enteritidis IgYs reduce 
contamination of eggs from previously 
infected chickens 
[159] 
 
 
Pseudomonas 
aeruginosa 
humans Anti-Pseudomonas aeruginosa IgYs 
prevents infections in cystic fibrosis 
patients 
[148] 
Staphylococcus 
aureus 
humans Anti-enerotoxin B-IgYs protected 
monkeys from lethal effect of S.aureus 
toxin 
[149] 
cattle Anti-Staphylococcus areus IgYs reduced 
symptoms of mastitis caused by S.aureus 
[160] 
Clostridium spp. humans IgYs generated against enterotoxin A 
block its activity in vivo and IgYs against 
Clostridium perfringens inhibit growth of 
its vegetative cells or spores 
[150] 
[162] 
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Campylobacter jejuni chickens Campylobacter jejuni specific IgYs 
protects chickens from infection and 
decreases already existing 
Campylobacter jejuni infections 
[161] 
 
 
Vibrio cholerae humans Anti-01-, O139 and anti-cholera toxin B 
subunit protected mice from cholera 
infection 
[151] 
 
 
 
 
 
 
1.13. Oral Immunotherapy based on IgY 
The idea of oral administration of IgYs specific to pathogens would be definitely an 
attractive approach, especially against pathogens infecting the gastrointestinal track. 
Advantages of IgYs are summarized in Table 6. There are several human studies on IgY-based 
therapies e.g. against S.mutans, P.gingivalis, H.pylori, P.aeruginosa and C.albicans in which it 
was showed that IgYs have a big potential to prevent or decrease microbial infections. [145, 
146, 153, 154, 163, 164] 
Eggs as an everyday food product do not cause the risk of toxic side effects. Concerns 
about allergy reactions are not necessary, as typical egg white allergens like ovomucoid, 
lysozyme, ovalbumin and ovotransferrin, as well as egg yolk allergens like livetin, phosvitin 
and apovitillin are not present in an extracted and affinity purified IgYs batch. An IgY itself 
does not activate the mammalian complement system, does not interact with rheumatoid 
factors, proteins A and G, nor with mammalian Fc receptors. [116]  
Proteins undergo digestion reactions in the stomach and in the intestine, where 
pancreas secretes its proteolytic enzymes. In the stomach, pepsin breakdowns proteins into 
peptides and amino acids, whereas hydrochloric acid denatures proteins. In the intestine, two 
proteases are active: trypsin, which cut peptides at basic amino acids and chymotrypsin which 
cut peptides at aromatic amino acids. Researchers have investigated also IgY susceptibility to 
proteolytic digestion by proteases and acids. It was investigated that IgY is more sensitive than 
IgG to HCl denaturation and its activity drops down rapidly in pH between 3-4. [165–168] IgY 
might lose its specificity when passing the digestive route through stomach and pancreas. 
[169, 170] Although, it was observed that IgYs are more sensitive to pepsin digestion 
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compared to IgGs, they are less susceptible to proteolytic activity of trypsin and chymotrypsin. 
[165, 171] IgY stability is still maintained in high temperatures up to 60-70°C, moreover no 
decrease in IgY concentration was observed after cooking 6 min in 100°C. [18,165, 166, 168]  
Despite concerns about the inactivation of IgYs during the digestion process, it is 
observed that orally applied IgYs against pathogens still give promising results (chapter 
above). The stability of IgYs in harsh conditions can be increased by additives and different 
encapsulation methods. For example, added sorbitol can suppress the inactivation of IgY in 
low a pH. [167] Similar effects can be observed in the presence of sucralfate and sucrose. [172, 
173] Encapsulation using gelatin or chitosan-alginate capsules, methacrylic acid copolymer 
also prevent from proteolytic digestion and denaturation, keeping preserving IgY activity. 
[156, 174–176] 
 
 
 
Tab. 6. Advantages of IgYs. [18] 
 
 
 
 
1.14. Bioinformatic tools in the antibacterial immunotherapies design 
The main goal of bioinformatics is transfer, analysis and interpretation of the data 
resulted from experiments and study on genome, transcriptome and proteome. It combines 
fields such as biology, computer and mathematical sciences in order to store, maintain and 
translate the information generated in biotechnology, genetics and molecular biology. [177]  
• Specific antibody ready to be delivered into patient/organism of choice 
• Do not provoke allergic reactions 
• Cost-effective and convenient production 
• High yield (up to 25mg of IgYs per ml of egg yolk) 
• Stability (pH 3,5-11, 30-70°C) 
• High avidity 
• Low cross reactivity (in comparison to other polyclonal antibodies) 
• Method of production is not harmful for animals 
• Can be produced against mammalian proteins 
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In the development of a new immunotherapy against pathogens, in silico analysis of the 
bacterial proteome is essential. The most favored candidates as potential therapeutic 
antibody targets are molecules exposed on the bacterial surface or secreted proteins with 
virulence properties. In silico work mainly focuses on the identification of genes encoding 
these molecules and proteins, protein sequence analysis and algorithm-based prediction of 
antigenicity of full or fragmented molecules chosen for the antibodies development. [178]  
The fundaments in this field of research are publicly available databases of: complete 
bacterial genome sequences, protein sequences, function and active sites, as well as 3D 
macromolecular structures. Examples of such a data collections are as follow: NCBI, the 
National Center for Biotechnology Information https://www.ncbi.nlm.nih.gov/ , comprises 
data of genomes, genes, proteins and chemicals, including genome sequences and assemblies, 
mapped variations and markers, information from epigenomic studies, nucleotide sequences, 
sequence clusters, tools for the study of gene expression, protein sequences and structures, 
protein functional domains, catalog of chemical bioactivity, molecular pathways linked to 
activity of chemicals. [179]  
UniProt database http://www.uniprot.org/  includes literature protein information such 
as name, amino acid sequence, sequence clusters, biological function, interaction with 
different molecules, but also different variants and proteomes of different organisms.[180]   
RCSB Protein Data Bank www.rcsb.org is a source of information about 3D structure of 
proteins, nucleic acids and complex assemblies, based on X-ray crystallography, Cryo-EM and 
NMR spectroscopy. [181] Every protein has its unique UniProt and PDB identification number, 
additionally EC number when protein has enzymatic functionality.   With these IDs a detail 
definition of protein structure, active sites, substrate specificity, single amino acid residue 
function and their mutability is possible. There are several databases providing these 
information e.g. Catalytic Site Atlas https://www.ebi.ac.uk/thornton-srv/databases/CSA/ or 
HotSpot Wizard 1.7 https://loschmidt.chemi.muni.cz/hotspotwizard-1.7/. [182, 183] 
Moreover,  there are some informatic tools for individual analysis, modeling and molecular 
visualization e.g. UCSF Chimera https://www.cgl.ucsf.edu/chimera/ or Jmol 
http://jmol.sourceforge.net/. [52, 184] In the choice of the best antigen for antibody 
development, immunogenicity or hydrophobicity (more hydrophobic proteins are less 
antigenic) parameters analysis is very important. Helpful are programs such as e.g.:  Peptide 
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Property Calculator http://biotools.nubic.northwestern.edu/proteincalc.html  or ProtScale 
https://web.expasy.org/cgi-bin/protscale/protscale.pl . [185, 186] 
More database and bioinformatics tools depends on the research need or project nature 
can be found e.g. on ExPAsy – Bioinformatic Resource Portal https://www.expasy.org/. [187] 
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2. Aims 
 
 
 
 
2.1. General aims    
 In times of a worldwide increasing problem with fast developing new resistant bacterial 
strains and less and less effective antibiotic therapies, the perspective of establishing a 
universal IgY-based immunotherapeutics targeting ESBL-producing bacteria is a very 
promising alternative. Therefore, the aim of this study was to create a coherent system based 
on already established biological and chemical components, to prove the concept that specific 
IgYs designed with the help of in silico tools can be a good candidate for an oral passive 
immunotherapeutic against ESBL-producing gram negative bacteria. Another aim was to show 
that it is possible to inhibit the growth of these bacteria using different IgY-based strategies: 
IgYs targeting bacterial cell surface and IgYs targeting ß-lactamase. As the family of ESBLs 
constantly grows and there is lack of their clear classification in the literature, this study 
intended to develop a model based on ESBL parental enzyme TEM-1 ß-lactamase (class A) and 
TEM-1 producing E.coli strain. Subsequently, to use this model to evaluate the properties of 
in-house designed specific IgYs. The project was divided into 3 sections.  
 
  
2.1.1. Analysis of TEM-1 by bioinformatic approaches 
The main aim of this part was to analyze the amino acid sequence and conformation of 
ß-lactamase TEM-1 in comparison to TEM- type ESBLs using different bioinformatic tools, in 
detail to identify active site and conservative residues. Based on this information, another aim 
was to design in silico short peptides mimicking amino acid sequence of TEM-1 active site. 
 
2.1.2. Antigen preparation for chicken immunization and IgY development  
In this section the aim was to develop different IgYs, according to designed strategies 
for an oral passive immunization against TEM-1 producing E.coli, as a potential complement 
or as a replacement for the existing antibiotic therapy. Chosen strategies were as follow: a) 
IgYs as a complement to antibiotics - inactivation of TEM-1 by targeting the whole enzyme or 
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inactivation of TEM-1 by targeting the active site, b) IgYs as a replacement for antibiotics - 
neutralization of bacteria by targeting surface molecules. The objective of this part was to 
prepare different antigens for the chicken immunization in order to develop IgYs against: 
whole TEM-1 protein, short peptides mimicking active site, inactivated TEM-1-producing 
E.coli.   
Another aim was to develop the most effective and specific IgYs, therefore these 
targeting the enzyme were extracted independently at two different levels: purified by 
precipitation methods and affinity purified, and these targeting bacteria were developed 
separately against E.coli inactivated by two different methods: heat and e-beam inactivation, 
and affinity purified. 
 
 
2.1.3. Characterization and functional studies on IgYs developed against TEM-1 
producing E.coli 
In this section the aim was to compare IgYs with IgG by sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis. Furthermore, to investigate the specificity and activity of 
developed IgYs against different targets in vitro by ELISA and inhibition assay. Additional 
objective was to visualize the binding of generated IgYs to a target, using the 
immunofluorescence staining method. 
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3. Materials and methods 
 
 
 
3.1. Study design 
 Two main strategies using specific IgYs were designed in this study to inhibit the growth of TEM-
1 producing E.coli. The first strategy was to inactivate the TEM-1 by specific IgYs and kill the E.coli in 
the presence of ampicillin (described in subchapter 2.1.2 as a complementary strategy). For this, the 
two types of IgYs were generated: 1) targeting the active site, developed by immunization of a chicken 
with a short peptide synthesized de novo resembling the aminoacidic sequence surrounding critical 
catalytic residues of TEM-1 analyzed with bioinformatic approaches, 2) targeting the whole TEM-1 
structure , developed by immunizing the chicken with purified recombinant TEM-1 protein. The second 
strategy was to eradicate the TEM-1-producing E.coli by inhibiting their biological processes with IgYs 
specific to the bacterial cell surface (described in subchapter 2.1.2. as an alternative strategy to 
antibiotics), which were generated by immunization of the chicken with inactivated whole cells of TEM-
1-producing E.coli. Both strategies are shown on the Fig. 17. 
 
 
 
 
 
 
Fig. 17. Two strategies based on specific IgYs designed and developed in this study against TEM-1- producing 
E.coli. 
 58 Development of candidate IgY antibodies against ESBL-producing gram-negative bacteria for oral therapy 
3.2. Bioinformatic approach in target analysis for IgY development 
 
 
3.2.1. Analysis of TEM-1  
Amino acid sequence analysis of TEM-1 protein was performed using UniProt [180] (access id 
P62593) and RCBS PDB [181] (access id 1axb and 1btl). The  catalytic sites and conservative residues 
were identified using Hydrolases Catalytic Sites database [188], Catalytic Site Atlas [182] and HotSpot 
Wizard [183], additionally complemented by analysis of Lahey ß-lactamase data base. [34] Protein 
visualization was performed by using Chimera software. [52] The summary of information of TEM-1 is 
shown in table 7.  
 
         Tab.7. 
E.C. name Beta lactamase TEM-1 
E.C. number 3.5.2.6. 
Source organism Escherichia coli 
Weight 28,98kDa 
Length 263 amino acids 
Residues UniProt: 24-286, PBD: 26-288 
UniProtID P62593 
PDB Entry 1axb, 1btl 
 
 
3.2.2. In silico design of short peptides for IgY development  
Based on the bioinformatic analysis of active site of TEM-1 (described above), two 11-amino-
acid-long sequences containing specific conserved catalytic residues were selected for peptide 
synthesis in order to mimic the active site as antigens for specific IgYs development. The sequences 
chosen were as follow: 1- RFPMMSTFKVL and 2- TRLDRWEPELN. Visualization of amino acid sequences 
1 and 2 within TEM-1 as well as visualization of catalytic residues was performed by using Chimera 
software. [52] Antigenic properties of chosen sequences were tested by Antigen Profiler Peptide Tool 
(Thermofisher online tool, https://www.thermofisher.com/de/de/home/life-
science/antibodies/custom-antibodies/custom-antibody-production/antigen-profiler-antigen-
preparation.html).  
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3.3. Bacterial strain and culture  
 
 
3.3.1. Cultivation conditions 
A strain of the TEM-1 expressing E.coli BW25113 ΔbamBΔtolC where TEM-1 gene was integrated 
behind the bla promoter was a gift from Prof. PhD. Gerry Wright and Prof. PhD. Brian Coombes 
(Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Canada). 
Bacteria were cultured in Luria Bertani Broth LB medium (28713, Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany) with 0.1mg/ml ampicillin (11593027, Life Technologies GmbH, Darmstadt, 
Germany) for 18h, at 37˚C and with 150rpm. Streak plates were prepared by spreading the bacteria on 
LB-agar plate (19344, Sigma Aldrich Chemie GmbH) containing 0.1mg/ml ampicillin by sterile loop. 
Plates were incubated for 16h, at 37˚C and then kept at 4˚C. A single colony was picked to inoculate 5 
ml of LB medium (with 0.1 mg/ml ampicillin). The inoculation was incubated overnight on a shaker 
(37˚C, 150 rpm), transferred to a sterile conical flask containing 200ml of LB medium prewarmed to 
37˚C (with 0.1 mg/ml ampicillin) and kept on a shaker until bacteria reached OD600 ~0.4. Glycerol stocks 
were prepared by mixing liquid bacteria culture 1:1 (vol/vol) with 50% Glycerol (G5516, Sigma Aldrich 
Chemie GmbH, Taufkirchen, Germany) solution diluted with MiliQ water, and kept at -80˚C. The 
quantitive analysis of E.coli was done using a spread-plate method and establishing a bacterial growth 
curve. 
 
 
 
3.3.2. Colorimetric detection of TEM-1 in E.coli cell culture 
E.coli was cultivated as described in subchapter 3.2.1., transferred into tubes and kept on ice. 
Half of the samples were sonicated (2x cycles, 1min, power 70%), while the other half was left 
untreated. Next, the treated and untreated bacteria culture samples were diluted 1:2.5 (vol/vol) with 
PBS (P4417, Sigma Aldrich GmbH, Taufkirchen, Germany) transferred in triplicates to 96 well plate and 
mixed 8:1 (vol/vol) with 0,5mg/ml Nitrocefin (2388-5, BioVision Inc. Milpitas, CA, USA) dissolved before 
in 0.1M PBS and DMSO (D4540, Sigma Aldrich GmbH, Taufkirchen, Germany) 200:1 (vol/vol). As 
controls, LB medium with 0.1mg/ml ampicillin and PBS were used, also mixed with Nitrocefin solution. 
Samples were incubated in room temperature for 30min, then photographed and measured for 
absorption in a plate reader at 486nm.  
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3.4. Antigen preparation  
 
 
3.4.1. TEM-1 and synthesis of short peptides p1, p2 
As an antigen for the development of TIgY and aTIgY against TEM-1 produced by E.coli, the 
Recombinant E.coli Beta lactamase TEM precursor protein was used (Ab67672, Abcam plc, Cambridge, 
UK). For the development of p1IgY and p2IgY/ap2IgY, amino acid sequences 1 and 2 (see 3.2.2) were 
synthesized de novo by Gallus Immunotech Inc., Fergus, ON, Canada and used as antigens. Short 
peptides sequences were: p1-RFPMMSTFKVL and p2-TRLDRWEPELN. Additionally, they were 
conjugated with KLH carrier through the thiol group of an additional Cys residue on -C end of the 
peptide to increase the immunogenicity of peptides. Peptides were purified on HPLC (p1- 96.8%, p2- 
95.7% purity), tested on MS (Mw p1= 1459.86 g/mol, p2= 1531.72 g/mol) and lyophilized. Short 
peptide for the development of ap2IgY was synthesized by Davids Biotechnologie GmbH, Regensburg, 
Germany and was as follow: p2´ – TRLDRWEPELN, conjugated with KLH carrier through the Thiol group 
of an additional Cys residue on -C end of the peptide. The peptide was purified on HPLC (95% purity), 
tested on MS (Mw p2´= 1531.72 g/mol) and lyophilized.   
 
 
 
3.4.2.  Whole bacterial cells antigens 
E.coli was cultivated as described in subchapter 3.2.1 until OD600 reached  0̴.6. Cells were 
harvested by centrifugation for 10min at 4˚C, at 4000g washed twice with PBS and, subsequently, 
resuspended in PBS to obtain OD600 ≤ 3. Bacteria were inactivated independently by two methods: e-
beam (based on Low-Energy-Electron Irradiation) and heat inactivation. The e-beam inactivation of 
E.coli samples was performed as described by Fertey et al. using ionizing radiation dose of 5kGy (EBLab 
200, Comet, Flamatt, Switzerland).[189] For the heat inactivation, bacteria suspensions were 
incubated for 1h at 65˚C. Viability tests were performed by applying inactivated samples and control 
sample (untreated) on LB agar plates, subsequently incubated overnight at 37˚C. To fix and preserve 
cell membrane structures for subsequent immunization procedures, the heat and e-beam inactivated 
samples were treated with the Membrane Structure Conservation kit (K105, Davids Biotechnologie 
GmbH, Regensburg, Germany) according to manufacturer’s instruction. Each sample with different 
whole bacteria cell antigens contained ~8x10^8 CFU.  
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3.5. Chicken immunization and IgYs purification 
 
 
 
3.5.1. Generation of IgYs against TEM-1 and active site of TEM-1 
 
 
 
 
Fig. 18. A scheme of specific IgY generation against a) the active site of TEM-1 ß-lactamase, which is based on 
immunization of chickens with de novo synthesized short peptides mimicking amino acid sequence of the active 
site, b) the whole TEM-1 ß-lactamase, which is based on chicken immunization with a whole protein (the 
Recombinant E.coli Beta lactamase TEM precursor protein). 
 
 
 
 
 
3.5.1.1. Generation of p1IgY, p2IgY and TIgY. 
Immunization and purification of p1IgY, p2IgY and TIgY was customized and performed by Gallus 
Immunotech Inc., Fergus, ON, Canada. Chicken were immunized separately with purified short 
peptides p1, p2 and TEM precursor protein (shown on Fig. 18) in 4 2-week-long intervals, starting with 
primary immunization (1mg of antigen p1/p2/ TEM precursor protein in Freud`s complete Adjuvant) 
and 3 boosters (three times 0.33mg antigen p1/p2/ TEM precursor protein in Freud`s complete 
Adjuvant). After 2 weeks eggs were collected and IgYs were purified from egg yolk by a two-step 
precipitation, then diluted in PBS pH 7.3 containing 0.075% sodium azide. Three IgY fractions were 
obtained: p1IgY (28.4mg/ml), p2IgY (30.8mg/ml) and TIgY (27mg/ml).  
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3.5.1.2. Generation of ap2IgY and aTIgY with affinity purification step  
One of the methods to obtain a higher fraction of specific antibodies is affinity purification, 
which is used as additional step to standard precipitation protocols. Immunization and affinity 
purification of ap2IgY and aTIgY was customized and performed by Davids Biotechnologie GmbH, 
Regensburg, Germany. Chicken were immunized separately with purified short peptide antigen p2´ 
and the TEM precursor protein (shown on Fig. 18) in 4 2-week-long intervals. Eggs were collected after 
10-15 days after the last immunization, egg yolk was separated, IgYs were precipitated and specific 
IgYs were affinity purified using the antigen (p2’ or TEM precursor protein) immobilized on the resin. 
IgY fractions were diluted with PBS containing 0.02% sodium azide to the final concentration of: ap2IgY 
(0.41mg/ml), aTIgY (0.35mg/ml). 
 
 
 
3.5.2. Generation of eIgY and hIgY against TEM-1 producing E.coli with affinity 
purification step 
Immunization and affinity purification of eIgY and hTIgY was customized and performed by 
Davids Biotechnologie GmbH, Regensburg, Germany. Chicken were immunized separately with 
prepared whole bacterial cell antigens (shown on Fig.19): E.coli inactivated by e-beam and heat in 4 2-
week-long intervals. Eggs were collected 10-15 days after the last immunization. The egg yolk was then 
separated, IgYs were precipitated and specific IgYs were affinity purified using the antigen immobilized 
on the resin (each type of inactivated bacteria cells). IgY fractions were diluted with PBS containing 
0.02% sodium azide to the final concentration of: eIgY (0.51mg/ml) and hIgY (0.48mg/ml).  
 
 
Fig. 19. A scheme of specific IgY generation against E.coli cell surface proteins which is based on 
immunization of chickens with E.coli whole cell antigens, prepared by inactivation by two methods: heat and e-
beam.  
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3.5.3. Non-specific IgYs: rIgY 
In the study, non-specific IgYs were used as a control. They were purified from non- or pre-
immunized chickens and were as follow: rIIgY (LOT16IgY014E-pi, Gallus Immunotech), rIIIgY 
(LOT16IgY015E-pi), rIIIIgY (P075.05, Davids Biotechnologie), rIVIgY (16IgY014K-pi, Gallus Immunotech). 
 
 
 
 
3.6. Characteristics of IgYs 
 
 
 
3.6.1. SDS -PAGE: reduced and non-reduced 
Comparison of molecular weight, heavy and light chains, and purity between p1IgY, p2IgY, rIIgY, 
rIIIgY, rIIIIgY, rIVIgY, TIgY and IgG1 AQP1 (sc-25287, Santa Cruz) was performed by Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in reduced and non-reduced conditions using 
4-15% Mini PROTEAN TGX Stain-Free Protein Gells (4568085, Bio-Rad Laboratories GmbH, Münich, 
Germany) and applying 200 V for 30min. SDS-page running  buffer was prepared by mixing 1/10 10x 
TGS running buffer (161-0732, Bio-Rad Laboratories GmbH, Münich, Germany) with miliQ water. For 
non-reduced conditions samples were mixed 1:1 (vol/vol) with 2x Laemmli sample buffer (161-0737, 
Bio-Rad Laboratories GmbH, Münich, Germany). For reduced conditions, samples were mixed 1:1 
(vol/vol) with 2x Laemmli sample buffer previously mixed 20:1 (vol/vol) with ß-mercaptoethanol. 
Before loading on the gel, samples were incubated at 95˚C for 5min and cooled down on ice. Two 
standards were used to estimate the size of immunoglobulins: Precision Plus ProteinTM Standards 
unstained (161-0363, Bio-Rad Laboratories, München, Germany) and Precision Plus ProteinTM 
Standards All Blue (161-0373, Bio-Rad Laboratories, München, Germany).  The protein bands were 
visualized by applying a UV light. 
 
 
3.6.2. ELISA  
 
3.6.2.1. Binding specificity of TIgY, p1IgY, p2IgY and rIgY to the Beta 
lactamase TEM precursor protein 
To determine the specific activity of TIgY, p1IgY and p2IgY against the Beta lactamase TEM 
precursor protein and to choose which short-peptide-based IgY (p1 or p2) binds better to the active 
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site of this protein, an indirect ELISA assay was performed (the scheme is shown on Fig. 20 a). A 96 well 
plate was coated with 100µl of 1ug/ml the Beta lactamase TEM precursor protein diluted in coating 
buffer carbonate-bicarbonate buffer (prepared according to manufacturer, pH 9,6, BUF030A, Bio-Rad 
AbD Serotec GmbH, Puchheim, Germany) and incubated overnight at 4˚C. The plate was washed three 
times with washing buffer - PBS buffer containing 0.05%(vol/vol) Tween®-20 (P9416, Sigma Aldrich 
Chemie GmbH, Taufkirchen, Gemrnay) and blocked for 2h at RT with 200µl of blocking buffer-PBS 
buffer containing 0.05%(vol/vol) Tween®-20 and 2% (w/vol) non-fat milk powder (T145.2, Carl Roth, 
Germany). Next, the plate was washed three times with washing buffer and thereafter, specific IgYs 
(TIgY, p1IgY, p2IgY) and non-specific rIVIgY used as a control were diluted to 200µg/ml with diluent 
buffer-PBS buffer containing 0.05%(vol/vol) Tween®-20 and 0.3% (w/vol) non-fat milk powder, and 
were loaded by multichannel pipette in three technical replicates per sample on the 96 well plate in 
serial 2-fold dilutions, mixed 10 times and with a change of tips between each dilution.  As the next 
step, plate was incubated for 2h at RT and washed again three times with washing buffer. Afterwards, 
100µl of secondary antibody anti-chicken IgY rabbit IgG with horse radish peroxidase conjugate (SA1-
9509, Thermo Fisher) diluted 1:5000 (vol/vol) with diluent buffer and was added to each well and 
incubated for 1h at 37˚C. Plate was washed again three times with washing buffer, then 100µl of the 
substrate solution TMB Core+ (BUF062a, Bio-Rad AbD Serotec GmbH, Puchheim, Germany) for HRP-
conjugated antibodies was added to each well and incubated for 10min at RT in the dark. The reaction 
was stopped by adding 50µl of 0.2M sulfuric acid (diluted with MiliQ, 1,09072.1000, Sigma-Aldrich, 
Taufkirchen, Germany) to each well and absorbance of samples was measured at 450nm. ELISA assay 
was repeated three times (n=3) and values were plotted.   
 
 
 
3.6.2.2. Binding specificity of TIgY, p2IgY and rIgY to TEM-1 in E.coli lysate 
After the first selection of IgYs specific to the Beta lactamase TEM precursor protein, the next 
step was to determine the specific activity of TIgY and p2IgY against ß-lactamase TEM-1 produced by 
E.coli in cell culture. Therefore an indirect ELISA assay was performed using E.coli cell lysate (the 
scheme is shown on Fig. 20 b). To prepare E.coli cell lysate, bacteria were cultivated as described in 
subchapter 3.2.1. Then aliquots of cell suspension were sonicated on ice in 2 cycles, 1min, applying 
70% of power. Cell lysate was diluted with coating buffer 1:32 (vol:vol) what corresponded to ~1.2x106 
CFU/ml, and used to coat a 96 well plate, by loading 100µl per well. The plate was incubated overnight 
at 4˚C. Plate was washed three times with washing buffer and blocked for 2h at RT with 200µl of 
blocking buffer. Next, the plate was washed again three times with washing buffer. Thereafter, specific 
IgYs (TIgY and p2IgY) and non-specific rIVIgY used as a control were diluted to 200µg/ml with diluent 
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buffer. The next steps were preceded as described in subchapter 3.6.2.1. ELISA assay was repeated 
two times (n=2) and values were plotted.   
 
 
 
 
3.6.2.3. Binding specificity of aTIgY, ap2IgY and rIgY to TEM-1 in E.coli lysate 
In order to determine the specific activity of affinity purified aTIgY and ap2IgY against ß-
lactamase TEM-1 produced by E.coli in a cell culture, an indirect ELISA assay was performed using E.coli 
cell lysate (the scheme is shown on Fig. 20 c). To prepare E.coli cell lysate, bacteria were cultivated as 
described in subchapter 3.2.1. Then aliquots of cell suspension were sonicated on ice in 2 cycles, for 
1min., applying 70% of power. The cell lysate was diluted with coating buffer 1:25 (vol:vol) what 
corresponded to ~1.5x106 CFU/ml, and was used to coat the 96 well plate, by loading 100µl per well. 
The plate was incubated overnight at 4˚C. Plate was washed three times with washing buffer and 
blocked for 2h at RT with 200µl of blocking buffer. Next, the plate was washed again three times with 
washing buffer. Thereafter, specific IgYs (TIgY and p2IgY) and non-specific rIIIIgY used as a control were 
diluted to 80µg/ml with diluent buffer. The next steps were preceded as described in subchapter 
3.6.2.1. ELISA assay was repeated three times (n=3) and values were plotted.   
 
 
 
3.6.2.4. Binding specificity of hIgY, eIgY, rIgY to E.coli  
To determine the specific activity of affinity purified IgYs against inactivated by heat and e-beam 
TEM-1 producing E.coli, such as hIgY and eIgY respectively, an indirect bacterial ELISA assay was 
performed (the scheme is shown on Fig. 20 d). For this E.coli were cultivated as described in subchapter 
3.2.1., cells were harvested by centrifugation at 4˚C, for 10min, at 4000g, washed twice with 1PBS and 
incubated in 4% (vol/vol) formaldehyde in 1xPBS at RT for 20min. Next, the cells were washed three 
times with PBS. Thereafter, E.coli cells were diluted with coating buffer 1:25 (vol:vol) to ~1.5x106 
CFU/ml, and suspension was used to coat a 96 well plate, loaded 100µl per well. The plate was 
incubated overnight at 4˚C. As the next step, the plate was washed three times with washing buffer 
and blocked for 2h at RT with 200µl of blocking buffer. Then, the plate was washed three times with 
washing buffer and thereafter, specific IgYs (hIgY and eIgY) and non-specific rIIIIgY used as a control 
were diluted to 80µg/ml with diluent buffer. The next steps were preceded as described in subchapter 
3.6.2.1. ELISA assay was repeated three times (n=3) and values were plotted.   
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Fig. 20. Different indirect ELISA set-ups to study the binding specificity of developed IgYs: a)  TIgY, p1IgY, 
p2IgY and rIgY to the Beta lactamase TEM precursor protein, b) TIgY, p2IgY and rIgY to TEM-1 in E.coli lysate, c) 
aTIgY, ap2IgY and rIgY to TEM-1 in E.coli lysate, d) hTIgY, eIgY and rIgY to bacteria cell surface of E.coli. In all 
studies as a secondary antibodies anti-chicken IgG were used, additionally conjugated with horse radish 
peroxidase for the binding detection.  
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3.7. In vitro studies on IgYs 
 
 
 
3.7.1. Inhibition assay 
To investigate the influence of developed IgYs on growth of TEM-1 producing E.coli an inhibition 
assay was performed, in which E.coli inoculates, were incubated for 24h in the presence of p2IgY, TIgY, 
ap2IgY, aTIgY, hIgY and eIgY. As controls LB medium (no IgY) and non-specific IgYs were used (rIIgY or 
rIIIIgY). To compare the growth of E.coli after incubation with different IgYs, the drop plate method for 
colony counting was used (adapted from Chen et al. 2003 and modified). [190] From each mixture 3x 
200µl of aliquots was taken using multichannel pipette to prepare drop plates (Agar + 0.1 mg/ml 
ampicillin) at the time points of incubation: 0h, 3h, 6h and 24h. The 10-fold serial dilutions (100-106) 
were made by transferring by multichannel pipette 20µl of mixtures to a well containing 180µl of LB 
medium with 0.1mg/ml ampicillin, mixing 10 times, repeating the process and changing tips between 
dilutions. Three replicates of 20µl from each of selected dilutions were plated onto agar plates. Plates 
with samples from each time point were first incubated for 3h at RT and then incubated for 16h at 
37˚C. Colony-forming units were counted to calculate the total number of bacteria colony-forming 
units per ml of sample for each incubation time point and then were plotted. Additionally, the growth 
of bacterial cells in mixtures was monitored by bacterial density measurements at OD600 at each 
incubation time point and optically through visual changes. The scheme of the method is shown on 
the fig. 21 a and 21 b.  
 
 
 
Fig. 21a. A scheme of the inhibition assay and the drop plate method.  
 
 
 68 Development of candidate IgY antibodies against ESBL-producing gram-negative bacteria for oral therapy 
 
Fig. 21b. A scheme of the inhibition assay and the drop plate method.  
 
 
 
3.7.1.1. Influence of p2IgY and TIgY on the growth of TEM-1 producing E.coli  
E.coli were cultivated as described in subchapter 3.2.1. The bacteria cell suspension was 
adjusted to OD600   0̴.05 corresponding to a cell density of  2̴ × 106 cfu/ml. Specific IgYs solutions: p2IgY 
and TIgY were diluted with LB medium containing 0,1mg/ml ampicillin, to 10mg/ml. As a negative 
control a non-specific 10 mg/ml rIIgY solution was used, and LB medium with 0.1mg/ml ampicillin 
without IgY was used as a blank. All the IgY solutions were mechanically sterilized using 0.22-µm 
membrane syringe filters. Each IgY solution and control were mixed 1:1 with a prepared E.coli 
suspension. Mixtures were incubated for 24h at 37˚C and 150rpm. At the time points 0h, 3h, 6h and 
24h of incubation OD600 values of each mixture were measured, aliquots were taken and drop plates 
were prepared (n=6) in the way as described at the beginning of this chapter. Colony-forming units for 
each sample at all incubation time points were counted, total number of bacteria colony-forming units 
per ml for each incubation time point was calculated and plotted. 
 
 
 
3.7.1.2. Influence of ap2IgY and aTIgY on the growth of TEM-1 producing 
E.coli 
E.coli were cultivated as described in subchapter 3.2.1. The bacteria cell suspension was 
adjusted to OD600  0̴.05 corresponding to a cell density of  2̴ × 106 cfu/ml. Specific IgYs solutions: ap2IgY 
and aTIgY were diluted with LB medium containing 0,1mg/ml ampicillin, to 0.2 mg/ml. As a negative 
control a non-specific 0.2mg/ml rIVIgY solution was used, and LB medium with 0.1mg/ml ampicillin 
without IgY was used as a blank. All the IgY solutions were mechanically sterilized using 0.22-µm 
membrane syringe filters. Each IgY solution and control were mixed 1:1 (vol/vol) with prepared E.coli 
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suspension. Mixtures were incubated for 24h at 37˚C and 150rpm. At the time points  0h, 3h, 6h and 
24h of incubation OD600 values of each mixture were measured, aliquots were taken and drop plates 
were prepared (n=3) in the way as described at the beginning of this chapter. Colony-forming units for 
each sample at all incubation time points were counted, total number of bacteria colony-forming units 
per ml for each incubation time point was calculated and plotted. 
 
 
 
3.7.1.3. Influence of hIgY and eIgY on the growth of TEM-1 producing E.coli 
E.coli were cultivated as described in subchapter 3.2.1. The bacteria cell suspension was 
adjusted to OD600   0̴.05 corresponding to a cell density of  2̴ × 106 cfu/ml. Specific IgYs solutions: h2IgY 
and eTIgY were diluted with LB medium without ampicillin, to 0.2 mg/ml. As a negative control a non-
specific 0.2mg/ml rIVIgY solution was used, and LB medium without ampicillin and without IgY was used 
as a blank. All IgY solutions were mechanically sterilized using 0.22-µm membrane syringe filters. Each 
IgY solution and control were mixed 1:1 (vol/vol) with prepared E.coli suspension. Mixtures were 
incubated for 24h at 37˚C and 150rpm. At the time points 0h, 3h, 6h and 24h of incubation OD600 values 
of each mixture were measured, aliquots were taken and drop plates were prepared (n=3) in the way 
as described at the beginning of this chapter. Colony-forming units for each sample at all incubation 
time points were counted, total number of bacteria colony-forming units per ml for each incubation 
time point was calculated and plotted. 
 
 
 
3.7.2. Immunofluorescence staining 
 
3.7.2.1. Specific binding of hIgY and eIgY to surface of TEM-1producing E.coli 
E.coli were cultivated as described in subchapter 3.2.1 until OD600 reached 0.36. Cells were 
harvested by centrifugation at 4000g for 10min at 4˚C, washed twice with PBS and incubated in 4% 
formaldehyde in PBS, at RT for 20min. Subsequently, the cells were washed three times and 
resuspended in PBS. Fixed E.coli cells were incubated with primary antibodies diluted in 1xPBS 
containing 1% (w/vol)  BSA (A9418, Sigma-Aldrich Chemie, GmbH, Taufkirchen, Germany) for two 
different time periods: one hour at 4˚C  and overnight at 4˚C, with one of the three tested  
combinations: 1) eIgY +  goat anti-E.coli IgG (OBT0986, Bio-Rad AbD Serotec GmbH, Puchheim, 
Germany), 2) hIgY + goat anti-E.coli IgG, 3) rIIIIgY + anti-E.coli IgG. Then, samples were washed three 
times with PBS and incubated with secondary antibodies diluted in 1xPBS containing 1% (w/vol) BSA  
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in the dark for 1h at RT. Samples were washed three times with 1xPBS. Before applying them on a glass 
slides, the antifade reagent with DAPI was added (336939, Life Technologies Corporation). 
Visualization was performed on the Olympus IX81 inverted fluorescence microscope and using the 
CellF Software (Olympus, Aartselaar, Belgium). In the table 8 a detailed description of antibodies used 
in the staining is shown.  
 
 
 
3.7.2.2. Specific binding of ap2IgY and aTIgY to TEM-1in E.coli culture 
E.coli were cultivated as described in subchapter 3.2.1 until OD600 reached 0.37. Cells were 
harvested by centrifugation at 4000g for 10min at 4˚C, washed three times with PBS and incubated in 
4% formaldehyde in 1xPBS in RT for 20min. Washed three times and resuspended in 1xPBS containing 
1% (w/vol) BSA. Samples were permeabilized with 1xPBS containing 0.1% (vol/vol) Triton x-100 for 
10min at RT, then washed with PBS and blocked with 1xPBS containing 2% (w/vol) BSA, for 1h at RT, 
and then washed again in 1xPBS. Then, the samples were incubated with primary antibodies diluted in 
2% (w/vol) BSA with 1xPBS overnight at 4˚C in the one of the following four combinations: 1) aTIgY +  
goat anti-E.coli IgG, 2) ap2IgY + goat anti-E.coli IgG, 3) rIIIIgY + goat anti-E.coli IgG, 4) ß-lac IgG1 
(ab12251, Abcam plc, Cambridge, UK) + goat anti-E.coli IgG. Then samples were washed three times 
with PBS and incubated with secondary antibodies diluted in 1% (w/vol) BSA in PBS for 1h at RT, in the 
dark. Samples were washed three times with PBS and before applying them on the glass slides antifade 
reagent was added (336939, Life Technologies Corporation). Visualization was performed on the 
Olympus IX81 inverted fluorescence microscope and using the CellF Software (Olympus, Aartselaar, 
Belgium). In the table 9 a detailed description of antibodies used in the staining is shown. 
 
 
 
 
3.8. Statistical analysis 
All the data are presented as mean values ± SD. Statistical analysis for colorimetric detection of 
TEM-1 activity in E.coli culture was conducted using One-way ANOVA with Dunnett's multiple 
comparisons test. Statistical analysis of binding activity tests of IgYs via indirect ELISA were conducted 
using Two-way ANOVA with Bonferroni’s multiple comparisons tests. Statistical analysis of inhibition 
assays were conducted using Two-way ANOVA with Tukey’s multiple comparison tests. 
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Tab.8.  
Primary antibody Primary antibody type Concentration Secondary antibody Dilution 
eIgY Polyclonal chicken IgY, 
anti-E.coli inactivated 
by e-beam 5kGy 
(Davids 
Biotechnologie) 
50µg/ml Rabbit Anti-chicken 
IgY FITC (ab6749, 
Abcam) 
1:1000 
hIgY Polyclonal chicken IgY, 
anti-E.coli inactivated 
by heat (Davids, 
Biotechnologie) 
50µg/ml 
rIIIIgY Polyclonal chicken IgY, 
non-specific (P075.05, 
Davids 
Biotechnologie) 
50µg/ml 
anti-E.coli IgG Polyclonal goat IgG, 
anti-E.coli (OBT0986, 
Bio-Rad AbD Serotec 
GmbH) 
80µg/ml Donkey Anti-goat 
IgG Alexa fluor 594 
(705585147, 
Jackson 
Immunoresearch) 
1:500 
 
 
 
 
Tab.9. 
 
 
  
Primary antibody Primary antibody type Concentration Secondary antibody Dilution 
aTIgY Polyclonal chicken IgY, 
anti-recombinant ß-
lactamase precursor 
(Davids 
Biotechnologie) 
20µg/ml Rabbit Anti-chicken 
IgY FITC (ab6749, 
Abcam) 
1:1000 
ap2IgY Polyclonal chicken IgY, 
anti-p2 (Davids, 
Biotechnologie) 
20µg/ml 
rIIIIgY Polyclonal chicken IgY, 
non-specific (P075.05, 
Davids 
Biotechnologie) 
20µg/ml 
anti-E.coli IgG Polyclonal goat IgG, 
anti-E.coli (OBT0986 
Bio-Rad AbD Serotec 
GmbH) 
80µg/ml Donkey Anti-goat 
IgG Alexa fluor 594 
(705585147, 
Jackson 
Immunoresearch) 
1:500 
anti-ßlac IgG1 Monoclonal mouse 
IgG1, anti-ß-
lactamase (ab12251, 
Abcam) 
80ug/ml Donkey Anti-mouse 
IgG Alexa Fluor 488 
(A-21202, 
ThermoFisher 
Scientific) 
1:200 
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4. Results and discussion 
 
 
 
 
4.1.  Design of short peptides p1 and p2 for the development of IgYs against the 
active site of TEM-1 
The structure of TEM-1, the firstly discovered ß-lactamase, is well studied and described. [33, 
34] It is also classified as a parental enzyme for more than 200-member TEM group of ß-lactamases of 
which more than 86 were characterized as ESBLs. [36, 70, 81] To develop IgYs against TEM-1 active 
site, also with the perspective of targeting and inactivating TEM-1 mutants, the structure analysis was 
focused on the identification of low mutable amino acids residues playing important role in antibiotic 
hydrolysis process. Due to these requirements the sequences 1 and 2, containing these critical amino 
acids for TEM-1 activity, were chosen as a base for the p1IgY and p2IgY/ap2IgY development.  
 
 
4.1.1. Catalytic sites and conservative residues in TEM-1 structure identified as a 
potential target for IgYs 
Within the 263 amino acids of TEM-1, 7 amino acids are identified as important residues in 
catalytic site: S70, Lys73, Ser130, Lys234, Glu166, Asn170 and Ala237 (Fig.22). According to the 
literature, they have a specific role in the hydrolysis of ß-lactam antibiotics: Ser70 acts as a nucleophile 
in the attack on ß-lactam substrate carbonyl group, interacts with Glu166, stabilizes the tetrahedral 
intermediate during the process of acylation and deacylation and interacts with Lys73 by forming an 
ion pair together; Lys73 is involved in deprotonation of Ser70 actin as a general base in the acylation 
reaction and directs the hydroxyl group of S70 for the effective catalytic reaction, it also interacts with 
residue Glu166 through a hydrogen bond; Ser130 belongs to the hydrogen bonding network mediating 
protonation of the ß-lactam ring nitrogen and interacts with Lys234 and oxygen 12 from the 
carboxylate group of ß-lactam; Glu166 acts as a catalytic base towards the water molecule, what leads 
to deprotonation of Ser70 in the reaction of acylation and to the attack of the water molecule on the 
carbon of ß-lactam linked to the oxygen gamma of the residue S70 in the reaction of deacylation; 
Asn170 coordinates the water molecule by forming a hydrogen bond through its side chain and takes 
part in a proton transport from Ser70 to Lys73 in the acylation reaction; Lys234 recognizes ß-lactams 
at the initial step, electrostatically interacts with their carboxylate group and stabilizes transition states 
of the Michaelis-Menten complex, it also takes part in the protonation of ß-lactam nitrogen in the 
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acylation reaction and interacts with S130 via a hydrogen bond; Ala237 stabilizes a tetrahedral 
intermediate through the oxyanion hole which forms together with residue S70. [50, 54, 57, 60, 61, 
74, 182, 188, 191–196] 
The analysis with the Hot Spot Wizard shows that in the crystal structure of TEM-1 9 pockets can be 
found and the residues S70, S130, Lys234 and Ala237 all belong to the pocket 3 which is characterized 
as a catalytic pocket. The active site is situated between two domains of TEM-1 and consist of 4 
important structural elements: 1) helix H2 which forms a bottom of an active site, the residues S70 and 
K73 are located here, 2) the SDN loop which is between helix H4 and helix 5, containing the residue 
S130, 3) the strand S5 with the residues Lys234 and Ala237, and 4) Ω-loop between amino acids  164-
179 which forms a rim over the active site and contains residues Glu166 and Asn170. Additionally, the 
location of 7 residues in the different types of secondary structures was also analyzed: Ser70 and 
Asn170 are located on the 3(10) type of helix, Lys73 and Glu166 on the alpha helix, and Ser130, Lys234 
and Ala237 on the hydrogen-bonded beta strands. [183, 197] 
 
 
 
 
 
Fig. 22. The amino acid sequence of TEM-1 with 7 critical for the enzyme activity residues, highlighted in red: 
Ser70, Lys73, Ser130, Glu166, Asn170 , Lys 234 and Lys237. 
 
 
 
 
Another important parameter taken into account was the mutability score of the 7 chosen 
catalytic residues in order to find the ones with the lower probability of mutations and therefore 
developing new TEM mutants. The analysis with Hot Spot Wizard program showed that 6 out of 7 
residues were identified as conservative (low mutability): Ser70 (score 2), Lys73 (score 2), Ser130 
(score 2), Glu166 (score 3), Asn170 (score 2), Lys234 (score 3), (fig. 23 and fig. 24). 
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Fig. 23. Characteristics of Ser70, Lys73, Ser130, Glu166, Asn170 , Lys 234 and Lys237. Analysis done with the Hot 
Spot Wizard, revealed that the residue with the highest mutability score among the other was Ala237. 
Furthermore, it indicated that the possible exchange with amino acids: Ser, Gly, Cys or Thr might preserve the 
role of the residue in the active enzyme, or it can be even beneficial.  
 
 
 
   The mutability of the residue Ala237 was predicted at the level of 5 which is defined as 
moderate. When compared  this with Lahey data base (https://www.lahey.org/Studies/), the 
mutability of these residues among 223 of TEM-1 derivatives was as follow: Ser130 was substituted by 
Gly residue in derivatives TEM-59 (gene bank accession AF062386), TEM-76 (AF190694), CMT-3 
(AY039040) and by Thr in TEM-211 (KF513179); Glu166 residue was replaced by Gly in TEM-193 
(JN935135); Asn170 no substitutions were reported; Ala237 substituted by Thr in derivatives: TEM-5 
(no accession code), TEM-24 (X65253), TEM-86 (AJ277415), TEM-114 (AY589495), TEM-121 
(AY271264), TEM-130 (AJ866988), TEM-131 (AY436361), TEM-136 (AY826417), TEM-177 (FN652295) 
and by Gly in TEM-22 (Y17583). For the residues: Ser70 and Lys73 data were not shown, it might be 
due to their critical role and presence in the whole class A of ß-lactamases; for the Lys234 data were 
also not shown.  
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All these data were complemented with the research of Brown et al. 2009. They aligned the 
amino acid sequences of the Ω-loop of different representatives of ß-lactamases types from class A 
and it was established that more than 96% of ß-lactamases class A had the residue Asn at the position 
170 and all of them had the Glu at the position 166. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24. The 3D structure of TEM-1 with 6 conservative catalytic residues highlighted in different colors: Ser70 in 
light green, Lys73 in dark blue, Ser130 in red, Glu166 in torques, Asn170 in violet and Lys234 in yellow. The Ω-
loop including the Glu166 and the Asn170 is highlighted in pink.  
 
 
 
Based on the summary of this data analysis, the following optimal candidate target residues 
for the IgY development against the active site of TEM-1 were chosen: Ser70, Lys73, Glu166 and 
Asn170. All of them show low mutability tendency and they play a crucial role in ß-lactams hydrolysis. 
Moreover, they are situated in strategically good locations in TEM-1 structure (bottom of the active 
site and Ω-loop above the active site) and they could be paired, what was convenient for choosing the 
sequences for short peptides synthesis mimicking the active site.  
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4.1.2. Short peptides p1 and p2 mimic the functionally important structures of 
TEM-1 active site 
Two structures of the TEM-1 active site were chosen to be targeted by IgYs as the base for one 
of the strategies against E.coli producing TEM-1: the H2 helix and the Ω-loop. The length of sequences 
was 11 amino acids and they included previously identified and selected catalytic residues. Sequence 
1 (RFPMMSTFKVL) is placed between amino acids 65-75 from the H2 helix and includes residues Ser70 
and Lys73, sequence 2 (TRLDRWEPELN) is located between amino acids 160-170 from the Ω-loop and 
includes residues Glu166 and Asn170 (fig. 25 a and fig. 26 a).  
The choice of the length of the sequences was dictated by general requirements for the 
generation of IgYs. Sequences of 10-20 amino acids minimalize technical problems with the peptide 
synthesis. While anti-short-peptides antibodies are very specific to antigen, those based on sequences 
longer than 10 amino acids have higher chances to recognize the native structure of protein. Though, 
longer sequences increase the recognition of bigger number of epitopes.  There are several studies on 
specific IgYs against pathogens, more specifically, IgYs developed against virulent protein fragments or 
linear short peptides mimicking those, where their therapeutical properties were presented. 
Moreover, Shin et al. 2003 reported effectivity of IgYs against H. pylori that were developed against a 
15 amino-acids-short peptide mimicking Urease B, Schade et al. 1996 demonstrated the development 
of specific IgYs against 8 amino-acids cholecystokinin octapeptide for immunohistochemistry assays. 
[198–201] Based on these studies the length of 11 amino acids was chosen as the optimal.  
A very important parameter in generating specific antibodies is the antigenicity of the 
synthesized short peptides. It should be high enough to boost the immune response in immunized 
chickens in order to produce the required IgYs. To predict the antigenicity of short peptides p1 and p2, 
which correspond to chosen sequences 1 and 2 respectively, the algorithm-based Antigen Profiler 
Peptide Tool - provided online by Thermofisher- was used.  For the short peptides p1 and p2, the score 
for theoretical antigenicity was 3 and 4.1 respectively, what indicated their properties as ‘excellent 
antigens’ (fig. 25 b and fig. 26 b). Additionally, a 3D visualization of the sequence 1 and the sequence 
2 location in TEM-1 structure was done (fig. 25 c and fig. 26 c). It was necessary to show whether the 
developed p1IgYs (IgY against sequence 1) and p2IgYs (IgY against sequence 2) can potentially target 
these sequences in the 3D conformation of TEM-1. As it can be seen in fig. 27, the sequence 2 in the 
Ω-loop is more exposed than the hidden sequence 1, which potentially makes it an easier target. 
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Fig. 25. Sequence 1 in TEM-1. a) The chosen sequence was: RFPMMSTFKVL and contained Ser70 and Lys73. b) 
The peptide based on this sequence was recognized as an excellent antigen by Antigen Profiler Peptide Tool. c) 
The location of sequence 1 in 3D structure of TEM-1. 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) 
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Fig. 26. Sequence 2 in TEM-1. a) The chosen sequence was: TRLDRWEPELN located in the Ω-loop and contained 
Glu166 and Asn170. b) The peptide based on this sequence was recognized as an excellent antigen by Antigen 
Profiler Peptide Tool. c) The location of sequence 2 in 3D structure of TEM-1. 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) 
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Fig. 27. The location of sequence 1 (green) and sequence 2 (red)  in 3D structure of TEM-1.  
 
 
 
 
4.2. IgYs against ß-lactamase TEM-1 used as complement to antibiotic 
treatment reduced the growth of TEM-1- producing E.coli in vitro 
Previous studies showed that it is possible to inhibit the growth of bacteria by a treatment IgYs 
developed against toxins, subunits of toxins or recombinant protein structures mimicking virulent 
factors from the bacteria cell surface. [149, 150, 202, 203] Here, IgYs were developed against the whole 
ß-lactamase TEM-1 and the two structures within the active site, in order to inactivate the enzyme and 
allow antibiotic to eradicate the bacteria. The assumption of this set up was that blocking TEM-1 by 
IgYs will help ampicillin to overtake the E.coli resistance and kill the bacteria. 
To confirm the secretion and activity of TEM-1 by the E.coli used in this study, a control 
experiment was done using nitrocefin. This is a chromogenic cephalosporin sensitive for ß-lactamase 
activity. Due to the ß-lactam ring it possesses, it gets hydrolyzed in the presence of ß-lactamase and 
changes color from yellow to red. Out of the four tested samples, two showed the color change: cell 
lysate (CL) of TEM-1 producing E.coli changed the color from yellow to dark red, and E.coli cell culture 
(CC) to orange (Fig. 28, 2)). Samples of LB medium and PBS were used as controls and did not show 
any color changes. It means that TEM-1 activity was detected only in E.coli cell culture and E.coli cell 
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lysate. Additionally, the darker red color in the cell lysate which was correlated with a higher activity 
of the ß-lactamase, might confirm that TEM-1 is likely secreted into periplasmic space rather than 
extracellularly. [204] The samples were also tested spectrophotometrically (fig. 28, 1), where the 
values of absorption at 486nm for samples with E.coli cell lysate and E.coli cell culture were significantly 
higher when compared to control samples (PBS and LB medium). The absorption in the samples with 
E.coli cell lysate were significantly higher than for the E.coli cell culture (p<0.05).  
 
 
 
 
 
Fig. 28. Colorimetric detection of TEM-1 activity in E.coli cell culture (CC) and cell lysate (CL) in the presence of 
nitrocefin: 1) spectrophotometrically, 2) visually. E.coli were first cultivated in LB medium, then half of the 
samples were sonicated in order to obtain cell lysate. The other half was left untreated as samples of the cell 
culture. PBS and LB medium were used as controls. (LB n=6, CL n=3, CC=3, PBS n=6, p-values of less than 0.05 
were considered as statistically significant)  
 
 
4.2.1. Characteristics of specific IgYs purified by precipitation and their binding 
activity against TEM-1 
Even though the function of IgYs and IgGs is similar, due to their phylogenetical distance, they 
show many other differences (described in chapter 1.10). Structural difference can be clearly seen with 
SDS-page electrophoresis when some of the IgYs developed in this study are compared to IgG (fig. 29). 
1) 2) 
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In this method, the sodium dodecyl sulfate (SDS) imparts a negative charge to all the proteins and their 
separation is only due to differences in molecular weight.  
 
 
 
 
Fig. 29. Comparison of the structure bewteen IgYs and IgG by SDS-page electrophoresis in non-reduced 
and reduced conditions: 1- p1IgY, 2- IgG, 3- rIIIgY, 4- TIgY, 5- rIIgY, 6- rIIIIgY. Before loading on the gel, antibodies 
samples were mixed with Laemmli buffer, for the reduced condition additionally with ß-mercaptoethanol, and 
incubated at 95˚C for 5min. Separation of immunoglobulins and their elements in both set-ups was due to 
differences in molecular weight. The table shows the differences in molecular weight (Mw) of IgYs and IgG, their 
heavy chains (Hch) and light chains (Lch). 
 
 
 
In the non-reduced condition, clear black bands can be seen at the level of 180kDa for samples 
containing IgYs: p1IgY (IgY against peptide 1), rIIgY, rIIIgY, rIIIIgY (non-specific IgYs), TIgY (IgY against TEM-
1), and at the level of 160kDa for IgG. In the reduced condition, the presence of ß-mercaptoethanol 
disrupts the disulfide bonds between protein structures. Consequently, immunoglobulins were 
separated into structures of heavy and light chains. For IgYs, clear black bands could be seen at the 
level of 68kDa in the lanes 1,3,4,5 and 6, and for IgG at the level of 55kDa in the lane 2, indicating the 
presence of the heavy chains of each immunoglobulin type. Regarding the IgG light chains, a clear band 
was observed at the 25kDa. For IgYs, bands are smeared, but their bottom start below the IgG band, 
at around 22kDa and go above 25kDa.  
Results can be compared to the ones produced by Nasiri et al. and Amro et al.  [205, 206] 
Appearance of additional IgY bands or bands which are a bit smeared, in both reduced and non-
reduced SDS-page, might be due to the fact that IgG used in this experiment is a monoclonal affinity 
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purified antibody type, whereas IgYs p1IgY, rIIgY, rIIIgY, rIIIIgY, TIgY were not affinity purified and 
solution might have contained impurities from the egg yolk, other protein structures or not well 
developed IgYs. [206] For instance, bands around 40kDa might indicate the presence of C-terminal 
fragment of the vitellogenin II precursor.[207] 
At the first step of this study, IgYs against TEM-1 beta lactamase p1IgY, p2IgY and TIgY were 
purified by precipitation, which is the fastest and cheapest method for obtaining high amounts of 
IgYs.[116] The developed IgYs were analyzed via indirect ELISA using a twofold dilution series starting 
from a concentration of 200 µg/ml, firstly, to test their binding activity against the Beta lactamase TEM 
precursor protein (purified TEM-1) in order to choose the best binders, and, secondly, to test their 
activity towards TEM-1-producing E.coli lysate. 
At concentrations of 200-50 µg/ml, the ELISA results revealed a better binding ability of p2IgY 
and TIgY to purified TEM-1 compared to p1IgY and rIgY (a negative control)(p <0.05) (fig. 30, a). Below 
these concentrations, only TIgY showed the best binding capacity to purified TEM-1 amongst all tested 
antibody types. TIgY gave a signal even at a concentration as low as 1,56µg/ml. p1IgY was not able to 
bind to TEM-1. Based on this observation, p1IgY was excluded from further experiments. The reason 
why p1IgY did not bind to TEM-1 might be the location of sequence 1. It could be that the steric 
hindrances of the region around H2 helix made the location of the sequence 1 inaccessible for the 
specific p1IgY. Hence, p1IgY would not be able to reach the active site and potentially inactivate it. No 
non-specific binding of rIgY was observed.  
The results of the TEM-1-producing E.coli cell lysate ELISA showed that TIgY had the highest 
binding activity to TEM-1 present in the lysate (fig. 30, b). It was detected starting form the highest 
concentration of 200µg/ml until the concentration 6.25µg/ml (p<0.05). The reason why p2IgY binding 
was not detected in this set up might be that the concentration of TEM-1 secreted by E.coli is much 
lower than the concentration of purified TEM-1 applied in the previous setting (1µg/ml). No significant 
difference was showed between values for p2IgY and rIgY.  
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Fig.30. Comparison of binding activity between precipitation - purified IgYs against: a) TEM-1 (n=3, performed in 
triplicates) and b) the lysate of TEM-1-producing E.coli (n=2 performed in triplicates). In the first set-up a 96 well 
plate was coated with 1µg/ml of the Beta lactamase TEM precursor protein. In the second set-up the plate was 
coated with the lysate of TEM-1-producing E.coli obtained by sonication, in the concentration corresponding to 
~1.2x106 CFU/ml. As the primary antibodies p1IgY (precipitation-purified IgY against peptide 1), p2IgY 
(precipitation-purified IgY against peptide 2), TIgY (precipitation-purified IgY against TEM-1) and rIgY (non-
specific IgY) were used. Secondary anti-IgY antibodies were conjugated to a horse radish peroxidase for the 
binding visualization. (p-values of less than 0.05 were considered as statistically significant) 
a) 
b) 
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4.2.2. In vitro growth inhibition of TEM-producing E.coli by TEM-1-specific and 
precipitation-purified IgYs in the presence of ampicillin  
The inhibition assay where a TEM-1-producing E.coli liquid cell culture was incubated for 24h 
with 5mg/ml of p2IgY, TIgY and rIgY, in LB medium in the presence of ampicillin revealed that all of 
IgYs showed an inhibitory effect on the growth of TEM-1-producing E.coli. Similar results were 
obtained by Sugita et al., Tobias et al. and Shin et al., where specific IgYs purified by the precipitation 
method were used in vitro in a range of 1-10mg/ml against different pathogens and a decreased 
growth of bacteria was observed even after the treatment with unspecific IgYs. [147, 152, 157, 202] It 
might be due to the purification method: in a non-affinity purified population of IgYs, even up to ~98% 
of IgYs might be unspecific and it can increase over 99% when the chicken was immunized with a short 
peptide conjugated to KLH (according to the information of manufacturer 
http://gallusimmunotech.com/custom-services/affinity-purification).  
The OD600 measurements of E.coli liquid cultures with different treatments in the presence of 
ampicillin showed a significant decrease of bacteria cell density when incubated with TIgY, p2IgY and, 
interestingly, with rIgY,  in comparison to sample without the treatment - LB medium + ampicillin 
(p<0.05)(fig.31, a). Moreover, the inhibitory effect of TIgY and rIgY was greater than the one of p2IgY 
after 24h of incubation and the decrease in cell density was significantly higher (p<0.05).  At every 
specified time point of incubation (0h, 3, 6h and 24h), samples from each condition were drop-plated 
in serial dilutions in order to count the number of living bacteria as a colony forming unit. The CFU/ml 
in each liquid culture samples was calculated after the treatment with TEM-1-specific IgYs and controls. 
A representative example of drop plates established in this inhibition assay is showed on fig. 31, b. 
Results revealed that the treatment with p2IgY, TIgY, rIgY in the presence of ampicillin inhibited 
significantly the growth of TEM-1 producing E.coli when compared to sample without any treatment 
(LB + ampicillin) (p<0.05) (fig.32, a).  
Data were also plotted as logarithmic values to present how each of the treatments influenced 
the grow curves of TEM-1-producing E.coli (fig.32, b). It can be observed that the grow curve of E.coli 
incubated with TIgY dropped significantly in comparison to the rest of the samples. Also the treatment 
with rIgY decreased the growth of bacteria significantly. The result for p2IgY shows that the growth of 
E.coli was also inhibited but not as strongly as in samples treated with either TIgY or rIgY.  
These results might be falsely influenced though by the very high concentration of IgYs used in 
this study, and two explanatory hypothesis might be correlated with it: 1) when IgYs are purified with 
the precipitation method, the amount of highly specific antibodies is usually at the level of   2̴-16% of 
total IgYs what might have caused unspecific binding in the in vitro studies, especially, when the high 
concentration of antibodies were used, 2) to prepare such a high concentration of IgYs, more volume 
of original IgYs solution was used, contained up to 0.075% sodium azide, which might show toxic 
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effects towards E.coli cells. Consequently, this could have negatively influenced the growth of the 
bacteria. No toxicity test with IgY buffer were done in this study. 
 
 
Fig.31. The influence of precipitation-purified IgYs targeting TEM-1 mixed with ampicillin on the growth of TEM-
1-producing E.coli. a) The optical density measurement, (n=2, p-values of less than 0.05 were considered as 
statistically significant), b) the representative example of drop plates used for the calculation of colony forming 
unit. E.coli inoculates were incubated for 24h in the presence of 5mg/ml p2IgY and TIgY. As controls LB medium 
with ampicillin (no IgY) and non-specific IgYs were used (rIgY). To compare the growth of E.coli after incubation 
with different IgYs by the drop plate method, samples were taken at the time points: 0h, 3h, 6h and 24h. 
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Fig.32. Inhibitory effect of precipitation-purified IgYs targeting TEM-1 mixed with ampicillin, on TEM-1-producing 
E.coli: a) influence of different treatments on number of colony forming units, b) influence on growth curve. (n=6, 
p-values of less than 0.05 were considered as statistically significant) 
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4.2.3. Binding activity of affinity purified IgYs against TEM-1 
In order to increase the specificity of IgYs to the TEM-1 ß-lactamase and, therefore, decrease 
the high unspecific binding noticed in previous set-up, IgYs targeting the sequence 2 of the TEM-1 
active site  and targeting the whole enzyme TEM-1 were affinity purified, named ap2IgY and aTIgY, 
respectively. In a two-fold dilution series ELISA on the lysate of TEM-1-producing E.coli, starting from 
80µg/ml as the highest concentration, the results  revealed that among ap2IgY, rIgY and aTIgY, the 
latter showed the highest binding activity to TEM-1, (p<0.05) (fig.33.). Interestingly, these results show 
a similar tendency as precipitation purified TIgY. Although, it can be appreciated that due to the affinity 
purification the specificity increased. The aTIgY still showed binding specificity at a concentration of 
2.5 µg/ml, while the TIgY showed binding signal at the minimal concentration of 6.25 µg/ml.  
 
 
Fig.33. Comparison of binding activity between affinity-purified IgYs targeting TEM-1 against the lysate of TEM-
1-producing E.coli. The 96 well plate was coated with the lysate of TEM-1-producing E.coli obtained by sonication, 
in the concentration corresponding to ~1.2x106 CFU/ml. As the primary antibodies ap2IgY (affinity-purified IgY 
against peptide 2), aTIgY (affinity-purified IgY against TEM-1) and rIgY (non-specific IgY) were used. Secondary 
anti-IgY antibodies were conjugated to a horse radish peroxidase for the binding visualization.  (n=3 performed 
in triplicates, p-values of less than 0.05 were considered as statistically significant) 
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4.2.4. In vitro growth inhibition of TEM-1-producing E.coli by affinity purified IgYs 
specific to TEM-1 in the presence of ampicillin  
To test the influence of affinity-purified IgYs as a compound complementary to antibiotic on the 
growth of TEM-1-producing E.coli in vitro, an inhibition assay was performed by incubating TEM-1-
producing E.coli liquid cell culture for 24h with 0.1/ml of ap2IgY, aTIgY and rIgY in LB medium in the 
presence of ampicillin. It revealed that ap2IgY and aTIgY inhibited the growth of TEM-1-producing E.coli 
in culture. In fig.34 a pictures of the TEM-1-producing E.coli cell culture samples during the incubation 
with different IgYs after 6h and 24h are shown. Here, the color and transparency differences between 
the samples are noticeable: the appearance of the ap2IgY- and aTIgY-incubated cultures at the time 
point 6h and 24h of incubation were transparent, but the color was more intense and less transparent 
at 6h, even completely turbid at 24h when the cultures were incubated with rIgY or LB alone.  
These results correlated with the OD600 measurements, where a dramatical decrease of the E.coli 
cell density was observed after the ap2IgY and aTIgY treatment, while rIgY treatment had no effect on 
E.coli growth (fig.34 b). Importantly, this experiment requires more repeats for a reliable 
interpretation.  
Fig. 34 c shows a representative example of drop plates established in this inhibition assay. 
Results revealed that the treatment with ap2IgY and TIgY in the presence of ampicillin significantly 
decreased the number of CFU/ml in treated samples of TEM-1-producing E.coli cultures in comparison 
to rIgY and LB (p<0.05)(fig. 35 a). In this study, rIgY at the concentration of 0,1mg/ml did not show 
unspecific inhibitory effect. The logarithmic values showed that the growth curves of TEM-1-producing 
E.coli treated with ap2IgY and aTIgY had a decreasing tendency and were significantly different from 
those representing treatment with rIgY or LB alone (p<0.05)(fig. 35 b). 
These results showed that affinity purified ap2 and aTIgY developed against TEM-1, at low 
concentrations such as 0,1mg/ml and in the presence of ampicillin show inhibitory effect against TEM-
1 producing E.coli strain in vitro. It might be that ap2IgY and aTIgY target the active site and coat the 
whole enzyme, respectively, and as a consequence inactivate the TEM-1 so the ampicillin can eradicate 
the E.coli. However, the molecular details of this machinery have not been still investigated. 
Nevertheless, there are studies confirming neutralizing properties of specific IgYs against virulent 
proteins secreted by pathogens, e.g. Shiga toxin 2e produced by E.coli or Neurotoxin A produced by 
C.botulinum.[150, 203] Additionally, Shin et al. reported development of an effective IgY inactivating a 
secreted-by-H.pylori Urease B, based on de novo synthesised short peptide representing the 
enzyme.[199] No studies regarding development of IgYs to neutralise ß-lactamase was found though.  
Immunofluorescent staining microscopy photographs visualized the binding specificity of 
ap2IgY and aTIgY in comparison to commercially available monoclonal IgG1 against ß-lactamase, which 
was treated as a positive control and rIgY as a negative control.  
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Fig.34. The influence of affinity-purified IgYs targeting TEM-1 mixed with ampicillin on the growth of TEM-1-
producing E.coli. a) The visual changes in samples after 6 and 24h of incubation, b) optical density measurement, 
(n=1), c) the representative example of drop plates used for the calculation of colony forming unit. E.coli 
inoculates were incubated for 24h in the presence of 100µg/ml ap2IgY and aTIgY. As controls LB medium with 
ampicillin (no IgY) and non-specific IgYs were used (rIgY). To compare the growth of E.coli after incubation with 
different IgYs by the drop plate method, samples were taken at the time points: 0h, 3h, 6h and 24h. 
 
 
 
 
 
a) 
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Fig.35. Inhibitory effect of affinity-purified IgYs targeting TEM-1 mixed with ampicillin, on TEM-1-producing E.coli: 
a) influence on number of colony forming units, b) influence on growth curve. (n=3, p-values of less than 0.05 
were considered as statistically significant) 
4.2.5. Immunofluorescent staining of TEM-1 in E.coli using affinity purified IgYs  
Immunofluorescence staining was employed to visualize the binding specificity of ap2IgY and 
aTIgY to TEM-1 in formaldehyde-fixed E.coli (fig.36-38). Commercially available monoclonal IgG1 
against ß-lactamase was used as a positive control. Additionally, the E.coli-specific IgG was used to 
stain the surface of bacteria cells and rIgY as a negative control. Whereas E.coli-specific IgG stained the 
surface of all cells, ß-lactamase-IgG1 gave a signal in the periplasmatic space (fig. 36, upper picture).  
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The staining pattern of ß-lactamase-IgG1 observed here reproduces the observations of Rohde 
et al. [208] The negative control rIgY did not show any signal (fig. 36, bottom picture). Interesting 
observation was made in the samples stained by ap2IgY and aTIgY (fig. 37 and 38). In both cases, only 
small aggregates of E.coli cells which were distributed irregularly lit up (representative pictures were 
taken in two different areas). Also, aTIgY and p2IgY stainings were characterized by a a distinctive signal 
pattern. The aTIgY staining was spread and halo-shaped, while the ap2IgY signal was intensified in the 
cell poles.  In both cases, the signal coming from IgYs filled the bacteria shape detected by the E.coli-
specific IgG.  
These observations combined with the results of the inhibition assay indicate that ap2IgY and 
aTIgY might bind specifically with TEM-1. However, it differs from the reference ß-lactamase-IgG1. 
Several hypotheses are possible to explanation this discrepancy. One of them is that IgYs and ß-
lactamase IgG are possibly specific to two different conformations of TEM-1. ATIgY was developed 
against recombinant TEM-1 precursor protein lacking a 23 amino acids signaling sequence, which is 
important for transport from the cytoplasm through the membrane into the periplasm. This sequence 
is present in mature TEM-1. [209] During the translocation of the ß-lactamase from the cytoplasm to 
the periplasmatic space, the enzyme undergoes protein folding changes necessary to enter the 
hydrophobic environment of the membrane, and additional changes to exit in the polar, aqueous 
periplasm to become catalytically active ß-lactamase.[210, 211] It also includes the mechanism of 
hiding or exposing polar and non-polar residues by ß-lactamase while changing the structural location 
within the bacteria cell. [204] 
Another hypothesis might be a so called phenotypic heterogenicity or bistability of bacteria in 
one genetically homogeneous population. [212, 213] Both phenomena refer to the changes which 
randomly occur in some cells of the one population, distinguishing potent cells, what leads to the 
formation of two subpopulations e.g. expressing the same protein at different levels, or growing with 
different speed. It usually happens after rapid change of environment or as a response to a treatment. 
It leads to the assumption that in a given TEM-1-producing E.coli population, more potent cells 
expressing TEM-1 at different level were specifically targeted by ap2IgY and aTIgY during the 
immunofluorescent staining and neutralized during the inhibition assay. This hypothesis is the most 
probable, especially, that according to manufacturer, ß-lactamase-IgG1 is specific to the whole class A 
ß-lactamases and not exclusively to TEM-type. More investigation and supportive evidence is required 
to confirm this hypothesis, for example by combining immunofluorescent staining of TEM-1 producing 
E.coli using IgYs with TEM-1 mRNA FISH method (described by Rohde et al.) to compare the protein 
level and transcription among cells. [208] 
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Fig.36. Immunofluorescent staining of TEM-1 in TEM-1-producing E.coli culture, positive (upper) and negative 
(bottom) controls. Before staining, E.coli cells were permeablized with 0.1% Triton x-100. As the next step, E.coli 
were incubated with primary antibodies overnight (ßlac IgG1, anti-E.coli IgG, rIgY) and then incubated for 1h with 
secondary antibodies conjugated with fluorophores for the binding visualization. At the upper picture are: 
positive control staining with ß-lactamase-IgG1 (green) and E.coli-IgG (red), and merge of both. At the bottom 
picture are: negative control staining with rIgY (did not bind therefore there is no green signal) and E.coli-IgG 
(red), and merge of both. 
 
ß-lac IgG1 + anti-E.coli IgG 
 
rIgY + anti-E.coli IgG 
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Fig.37. Immunofluorescent staining of TEM-1 in TEM-1-producing E.coli culture with ap2IgY, pictures of two 
different areas are shown: E.coli-IgG (red), ap2IgY (green) and merge of both. Before staining, E.coli cells were 
permeablized with 0.1% Triton x-100. As the next step, E.coli were incubated with primary antibodies overnight 
(ap2IgY, anti-E.coli IgG) and then incubated for 1h with secondary antibodies conjugated with fluorophores for 
the binding visualization. 
 
ap2IgY + anti-E.coli IgG I 
 
ap2IgY + anti-E.coli IgG II 
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Fig.38. Immunofluorescent staining of TEM-1 in TEM-1-producing E.coli culture with aTIgY, pictures of two 
different areas are shown: E.coli-IgG (red), ap2IgY (green) and merge of both. . Before staining, E.coli cells were 
permeablized with 0.1% Triton x-100. As the next step, E.coli were incubated with primary antibodies overnight 
(aTIgY, anti-E.coli IgG) and then incubated for 1h with secondary antibodies conjugated with fluorophores for the 
binding visualization. 
 
aTIgY + anti-E.coli IgG I 
 
aTIgY + anti-E.coli IgG II 
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4.3. IgYs against ß-lactamase TEM-1-producing E.coli cells used as alternative 
to antibiotic treatment reduced the growth of E.coli in vitro 
The aim of this strategy was to target and inhibit the growth of TEM-1-producing E.coli by 
specific IgYs developed against their cell surface, without the presence of an antibiotic. There are 
several studies that reported good results in the treatment against bacteria with specific IgYs obtained 
after immunizing chickens with inactivated bacterial cells. [162, 202, 214, 215] IgYs produced with this 
method showed not only bacteria growth inhibitory potential but might also prevent the bacterial 
colonization by inhibiting their adhesion to epithelium cells. [216]  
To obtain highly specific IgYs towards the TEM-1-producing E.coli cell surface, two types of 
E.coli inactivation methods for IgY development were assessed. Heat inactivation is a common and 
effective method of killing bacteria and the temperature used ranges between 60 and 80˚C. The 
increased temperature cause denaturation of cellular components, such as DNA and ribosomes, and 
melting of membrane lipids what results in death of bacteria. It might negatively influence the 
preservation of antigens on the cell surface. [217, 218]   
The electron beam irradiation (E-beam) is based on low energy electron irradiation (LEEI) and 
it is a new method of inactivating pathogens. Since it preserves cell integrity and antigenic structures, 
it has a big potential in vaccine development. [189] As such, eIgY and hIgY were developed by 
immunization of chickens with either e-beam-inactivated or heat-treated (65°C) whole cells of TEM-1 
producing E.coli, respectively. Both types of antibodies were affinity-purified.  
This is the first study presenting the use of the E-beam in whole bacterial cell antigens 
preparation for the development of specific IgYs. After the inactivation of TEM-1-producing E.coli by 
E-beam at 5kGy or incubation at 65˚C for 1h, cells were tested for viability and compared with positive 
control – TEM-1-producing E.coli cultivated in LB. The results are shown in fig.39. Both inactivation 
methods were successful and no bacteria cell growth was observed, opposite to the positive control. 
Fig.39. Viability test of TEM-1-producing E.coli heat- and E-beam-inactivated in comparison to non-treated 
bacteria cells: a) no treatment, b) 65˚C 1h, c) e-beam.  
a) b) c) 
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4.3.1. Binding activity of affinity purified IgYs against TEM-1-producing E.coli  
In order to test the binding activity of the affinity-purified eIgY and hIgY against the TEM-1-
producing E.coli cell surface, indirect ELISA tests were performed against inactivated E.coli cells coated 
on the plate. The results of ELISA against TEM-1-producing E.coli fixed by 4% formaldehyde solution, 
revealed that eIgY bound better to E.coli cells than hIgY and rIgY (used as a negative control)(fig.40). In 
the two-fold dilution series starting with 80µg/ml as the highest IgY concentration, eIgY showed 
binding specificity down to the concentration of 1.25µg/ml and significantly differed from ap2IgY and 
rIgY (p<0.05). No significant difference was observed between values obtained with hIgY and rIgY.  
These results might indicate that eIgYs more specifically recognized TEM-1-producing E.coli cells, 
because the E-beam indeed preserved the integrity of cells and antigenic epitopes better, unlike the 
heat-inactivation which more likely disrupted the cell integrity and generated IgYs specific not only to 
the cell surface but also to the cell content.  
 
 
Fig.40. Comparison of binding activity between affinity-purified hIgY and eIgY targeting TEM-1-producing E.coli 
cells. The 96 well plate was coated with the TEM-1-producing E.coli cells previously inactivated with 4% 
formaldehyde solution, in the concentration corresponding to ~1.5x106 CFU/ml. As the primary antibodies hIgY 
(affinity-purified IgY against heat-inactivated E.coli), eIgY (affinity-purified IgY against e-beam inactivated E.coli) 
and rIgY (non-specific IgY) were used. Secondary anti-IgY antibodies were conjugated to a horse radish 
peroxidase for the binding visualization. (n=3 performed in triplicates, p-values of less than 0.05 were considered 
as statistically significant) 
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4.3.2. In vitro growth inhibition of TEM-1 producing E.coli by affinity purified IgYs 
specific to E.coli 
To test the influence of affinity-purified IgYs as a compound alternative to antibiotic on the 
growth of TEM-1-producing E.coli in vitro, an inhibition assay was performed, where the TEM-1-
prodcuing E.coli liquid cell cultures were incubated for 24h with 0.1/ml of either eIgY, hIgY or rIgY, 
diluted in LB medium without ampicillin. Interestingly, in a contrast to the ELISA results, both eIgY and 
hIgY inhibited the growth of TEM-1-producing E.coli in vitro. As expected, LB and rIgY treatment did 
not. Surprisingly, the results from OD600 measurement clearly did not support that observation: in all 
of the samples transparency and color changed over the time (fig.41 a).  
 
 
Fig.41. The influence of affinity-purified IgYs targeting TEM-1-producing E.coli cells on the growth of the same 
E.coli strain a) The visual changes in samples after 6 and 24h of incubation, b) optical density measurement, 
(n=1), c) the representative example of drop plates used for the calculation of colony forming unit. E.coli 
inoculates were incubated for 24h in the presence of 100µg/ml eIgY and hIgY. As controls LB medium without 
ampicillin (no IgY) and non-specific IgYs were used (rIgY). To compare the growth of E.coli after incubation with 
different IgYs by the drop plate method, samples were taken at the time points: 0h, 3h, 6h and 24h. 
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 The result of cell density measurement showed that the E.coli density grew for all of the samples 
(fig.41 b). After 24h, the color in all the samples with IgYs was similar, only LB turned darker, what 
might be due to metabolites from bacteria cells. Although, more repeats are needed to interpret these 
data. Fig. 41 c shows a representative example of drop plates established in this inhibition assay. The 
bacteria cell count revealed that the treatment with eIgY and hIgY significantly decreased the number 
of CFU/ml in samples treated with TEM-1-producing E.coli (p<0.05)(fig.42 a). Treatment with rIgY and 
LB expectedly did not. The growth curves with logarithmic values of TEM-1-producing E.coli showed a 
steady declination 6h after a treatment with eIgY or hIgY. Both were significantly different from those 
after treatment with rIgY and LB (p<0.05)(fig.42 b).  
These results might indicate that specific and affinity purified eIgY and hIgY developed against 
the cell surface of TEM-1-producing E.coli show the inhibitory effect on the TEM-1-producing E.coli in 
vitro at concentrations as low as 0.1mg/ml. These observations are comparable to a study of Sunwoo 
et al., where specific IgYs were developed against ETEC 987P E.coli. [214] Although these, were not 
based on the inactivated whole bacteria cell antigen but on the cell lysate. Compared to the current 
study, they used a similar IgY concentration for their inhibition test: 0.09mg/ml (in here 0.1mg/ml) but 
slightly different concertation of E.coli cells    ̴105 CFU/ml (in here    ̴2x106 CFU/ml). The mechanism of 
the growth inhibition of bacteria by eIgY and hTIgY was not explored. However, it might be that by 
targeting and adhering to the surface of E.coli, they blocked biological functions of bacteria, 
overlapped surface virulence factors and blocked the signaling between cells, what could result in the 
suppression of growth and multiplication. 
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Fig.42. Inhibitory effect of affinity-purified IgYs targeting TEM-1-producing E.coli cells on TEM-1-producing E.coli: 
a) influence on number of colony forming units, b) influence on growth curve. (n=3, p-values of less than 0.05 
were considered as statistically significant) 
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4.3.3. Immunofluorescent staining of TEM-1-producing E.coli using affinity-
purified IgYs developed against TEM-1-producing E.coli cells 
To visualize the binding activity of eIgY and hIgY to the cell surface of TEM-1-producing E.coli the 
immunofluorescence staining was employed (fig.43-45). As a positive control, the E.coli-specific 
monoclonal IgG was used, and as a negative control, a rIgY. DNA was stained with DAPI. The 
immunofluorescence staining was done in two ways: primary antibodies were either incubated for 1h 
or overnight.  The difference in signal intensity was not noticed between the incubation times, but due 
to technical problems amount of bacteria varies among samples.  
Both eIgY and hIgY showed specific binding to cell surface of TEM-1-producing E.coli, the signal 
was strong and clearly overlapping with the staining pattern given by the positive control (fig. 44 & 
45). Furthermore, the signal coming from a cell surface targeted by hIgY or eIgY, surrounded the DAPI 
signal inside the cell nicely. Importantly, rIgY did not give any signal meaning there was no unspecific 
binding (fig. 43). Additionally, subpopulations in TEM-1-producing E.coli were noticed on the fig. 43 
and 45 (white arrows), including the positive-control staining. It might have appeared due to 
phenotypic heterogenicity. [211, 212] According to this theory, within the one genetically 
homogeneous population of bacteria some phenotypic changes can occur. It may happen as a result 
of the stressful environmental conditions (e.g. presence of antibiotics, temperature changes or pH 
changes) or spontaneously. They can refer to many attributes and characteristics of bacteria, including 
e.g. enzymes, toxins, virulent factors expressed at the different level or it may appear as a change of 
growth speed among cells. It may result in the formation of two subpopulations, which might give later 
a different staining pattern within the same sample.  
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Fig.43. Immunofluorescent staining of TEM-1-producing E.coli cells, after 1h incubation (upper) and overnight 
incubation (bottom) with primary antibodies. Cultivated and harvested E.coli were first incubated with primary 
antibodies rIgY, anti-E.coli IgG (1h/overnight ) and then incubated for 1h with the secondary antibodies 
conjugated with fluorophores for the binding visualization. A positive control staining with E.coli-IgG (red), DAPI 
(blue), negative control staining with rIgY (no green signal detected) and merge of three. White arrows show cells 
subpopulations.  
 
DAPI + rIgY + anti-E.coli- IgG 1h 
 
DAPI + rIgY + anti-E.coli- IgG overnight 
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Fig.44. Immunofluorescent staining of TEM-1-producing E.coli cells, after 1h incubation (upper) and overnight 
incubation (bottom) with primary antibodies. Cultivated and harvested E.coli were first incubated with primary 
antibodies hIgY, anti-E.coli IgG (1h/overnight ) and then incubated for 1h with the secondary antibodies 
conjugated with fluorophores for the binding visualization.A positive control staining with E.coli-IgG (red), DAPI 
(blue), staining with hIgY (green) and merge of three. 
 
 
DAPI + hIgY + anti-E.coli- IgG overnight 
 
DAPI + hIgY + anti-E.coli- IgG 1h 
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Fig.45. Immunofluorescent staining of TEM-1-producing E.coli cells, after 1h incubation (upper) and overnight 
incubation (bottom) with primary antibodies. Cultivated and harvested E.coli were first incubated with primary 
antibodies eIgY, anti-E.coli IgG (1h/overnight ) and then incubated for 1h with the secondary antibodies 
conjugated with fluorophores for the binding visualization.A positive control staining with E.coli-IgG (red), DAPI 
(blue), staining with eIgY (green) and merge of three. White arrows show cells subpopulations. 
  
 
DAPI + eIgY + anti-E.coli- IgG 1h 
 
DAPI + eIgY + anti-E.coli- IgG overnight 
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5. Conclusions and perspectives 
 
 
 
 
This study presents a model system to develop specific IgYs against a therapeutic target of 
interest. Specifically, different types of IgYs were generated against ß-lactamase TEM-1-producing 
E.coli (BW25113 ΔbamBΔtolC)as a representative target and had the typical configuration of avian 
antibodies, were highly specific to their antigens and inhibited the growth of ß-lactamase TEM-1-
producing E.coli (BW25113 ΔbamBΔtolC) in vitro. Two strategies were design to target the TEM-1-
producing E.coli with IgYs: as a complement to antibiotics (IgYs against the enzyme TEM-1 used in 
combination with ampicillin) and as an alternative to antibiotics (IgYs against the bacteria TEM-1-
producing E.coli without the addition of ampicillin).  
In the first strategy, IgYs were developed against either the whole TEM-1 (TIgY and aTIgY) or only 
the active site of TEM-1 (p1IgY, p2IgY, ap1IgY and ap2IgY). For this, chickens were immunized with Beta 
lactamase TEM precursor protein and in silico designed short peptides mimicking the active site, 
respectively. Among 7 identified catalytic and conservative residues for TEM-group ß-lactamases, 2 
pairs of residues were chosen as a base for 2 11-amino-acid peptides synthesised to mimic the active 
site of TEM-1: Ser70 and Lys73 (Sequence 1 RFPMMSTFKVL, located on a H2 helix), and Glu166 and 
Asn170 (Sequence 2 TRLDRWEPELN, located on the Ω-loop). The ELISA tests revealed that among the 
precipitation-purified short peptides based IgYs, only p2IgY had a binding activity towards the active 
site of Beta lactamase TEM precursor protein. Moreover, TIgY showed the highest binding activity 
towards Beta lactamase TEM precursor protein among all precipitation-purified IgYs. Although, in the 
ELISA tests with TEM-1-producing E.coli lysate only TIgY and affinity-purified aTIgY showed binding 
activity compared to the other IgYs in their respective groups. Interestingly, not only TIgY (against TEM-
1), but also p2IgY (against sequence 2) showed an inhibitory effect on the growth of TEM-1-producing 
E.coli in vitro in the presence of ampicillin. Similar results were obtained with their affinity-purified 
counterparts (aTIgY and ap2IgY), however, using only a fraction of the concentration (5 mg/mL vs 0.1 
mg/mL). Their reactivity towards TEM-1-producing E.coli was confirmed by immunofluorescence. It 
might be that ap2IgY and aTIgY inactivate the TEM-1 by targeting the active site and building an 
antibody coat around the enzyme, respectively, and thereby preserve the antimicrobial activity of 
ampicillin. These hypotheses though, require further investigation. Nevertheless, these results indicate 
that the Ω-loop is potentially a good target for IgYs against TEM-1. 
 In the second strategy, IgYs were developed against TEM-1-producing E.coli. In this case, 
chickens were immunized with E.coli cells inactivated by one of the two methods: e-beam and heat 
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treatment. Although only eIgY showed binding activity compared to controls using in ELISA tests, both 
affinity-purified eIgY (e-beam) and hIgY (heat treatment) showed reactivity towards TEM-1-producing 
E.coli in the immunofluorescence assay and inhibited the bacteria’s growth in vitro without the 
presence of ampicillin. The observation could be explained by the possibility that IgYs developed 
against the bacteria surface, target the cells by building an antibody coat around them and, therefore, 
inhibit their biological functions.  
It is of interest to further determine the specificity of ap2IgY and aTIgY and confirm the presence 
of bacterial subpopulations with additional experiments. For instance, it would be beneficiary to 
explore the correlation between the protein detected by the IgYs and the gene expression pattern of 
TEM-1 by immunofluorescence and mRNA FISH, respectively.[208]  
Additionally, the stability and mutability of the TEM-1 gene construct in E.coli BW25113 
ΔbamBΔtolC should be tested and compared among the subpopulations observed in the 
immunofluorescence experiments, e.g. using the next generation sequencing. For this and other 
analysis, the subpopulation could be separated by fluorescence-activated cell sorting. Furthermore, 
the specificity of interaction between ap2IgY/aTIgY and TEM-1 could be tested by an in vitro inhibitory 
assay with non-ß-lactamase-producing E.coli strain and strains producing different class of ß-
lactamase. Also, a control inhibition assay without the presence of ampicillin could be performed. 
Subsequently, it would be advantageous to have an insight into a molecular interaction between IgYs 
and TEM-1. This could be done via binding affinity and kinetic tests using e.g. Plasmon Surface 
Resonance. Though, the screening assay should be design in the way to consider big molecular 
differences between ligand and analyte components (TEM-1   3̴0kDa, IgY 180 kDa).  
The cross-reactivity of hIgY and eIgY could be investigated by an inhibition assay with different 
bacteria species than E.coli and with samples where the E.coli BW25113 ΔbamBΔtolC would be mixed 
with other E.coli strains. It would also bring more insight into the effectivity of an antigen preservation 
of the heat and the e-beam methods used to inactivate the bacteria for chicken immunization and IgY 
production. To further explore the activity of these IgYs and their influence on the E.coli physiology, a 
bacterial flow cytometry can be performed using these and a panel of other markers. This method has 
many microbiological applications. [219]  
IgYs developed in this study might also be good candidates for further investigation as a broad-
spectrum treatment against a variety of ESBL-producing E.coli. The aTIgY which was developed against 
TEM-1 might also target its derivatives, as they have similar 3D structure with single amino acids 
mutations in the sequence. The ap2IgY was generated against catalytic and conservative residues, 
characteristic for the whole class A of ß-lactamases. It would be interesting to test these IgYs in vitro 
against patient’s E.coli isolates with TEM-ESBL profile. IgYs based on the heat and the e-beam 
inactivated bacteria could be newly developed against these isolates and tested.  
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To confirm the good inhibitory effect of (a)TIgY , (a)p2IgY, eIgY and hIgY on TEM-1-producing 
E.coli that was observed in-vitro, they should be further investigated in an animal infectious model to 
test their activity  complementary or alternatively to antibiotics in vivo. Several studies reported a 
positive effect of orally introduced specific IgYs against different bacteria in animal models, e.g. against 
C.difficile in hamster, H.pylori in mouse and E.coli in piglets.[140, 220–222] The ultimate intention of 
this research is to develop an effective and save IgY-based oral therapy for human patients against 
ESBL-producing gram negative bacteria. Human studies on specific IgYs delivered to patients orally 
showed a good effect against bacterial infections such as H.pylori or P.aeruginosa.[148, 154] 
As an egg’s component, IgYs are consider as save and non-toxic. An allergy to eggs can be 
overtaken by affinity purification, separating IgYs from other proteins. Additionally, immunotherapy 
does not cause bacterial resistance. Thereafter, in this context, two important parameters should be 
first studied: stability of the developed IgYs and absence of a gut microbiome shift after the treatment 
(to not disturb a gut’s flora balance).  As such, in an animal study, except an infection rate analysis after 
IgY treatment, a metabolic, stool tests, and next generation sequencing to monitor the gut flora change 
could be performed.  
An oral IgY therapy against ESBL-producing gram negative gastrointestinal bacteria would be of 
specific interest. It is that asymptomatic infection can spread to other localizations, such as lungs, 
urinary tract, blood system. Usually, these infections are already not responsive to standard antibiotics 
due to the previous antibiotic treatment and additionally they can be easily transmitted to other 
patients in hospitals. It is especially dangerous to chronically ill patients. [90, 223–225]  
Only one clinical study on IgYs treatment against ESBL-producing E.coli could be found, where 
the IgYs were developed against freeze-dried whole E.coli cells and administrated to hospital patients. 
[226] Unfortunately, due to the problems with the study design it could not be completed. 
Nevertheless, the study confirmed that the treatment with IgYs exhibited no toxic effects on patients; 
side effects which appeared were considered as mild. It also confirms a huge niche in this research 
field and an importance of developing IgYs against gastrointestinal ESBL-producing Enterobacteriaceae 
as a prophylaxis and a solution for decreasing effectivity of the antibiotic therapy. 
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 119 Summary 
The antibiotic resistance is developing faster than the development of new antibiotics, what 
increases the need of finding efficient alternative therapies. On the 27th of February 2017, WHO 
published the ‘Global priority list of antibiotic-resistant bacteria to guide research, discovery, and 
development of new antibiotics’ in Geneva, Switzerland. This document focuses on 12 antibiotic-
resistant bacteria, and among them the Extended Spectrum Beta-Lactamase (ESBL)-producing 
Enterobacteriaceae family (including E.coli) is classified to a group of the critical priority.  
The IgY technology (based on chicken polyclonal immunoglobulins Y – IgY) brings a lot of 
advantages in the fight against resistant bacteria including: a) fast and effective production of highly 
specific antibodies, b) reduction of risk of bacterial resistance to a therapy, c) do not activate the 
complement, do not bind to A and G proteins, mammalian antibodies like rheumatoid factors or 
human anti-murine antibodies, and the cell surface Fc receptor, d) are characterized by high stability, 
high avidity and low cross-reactivity. 
The general idea of this study was to develop candidate specific IgY antibodies for an oral 
therapy targeting the ESBL-producing gram negative bacteria. As the family of ESBLs constantly grows 
and there is lack of their clear classification in the literature, the specific aim was to build a proof of 
concept study based on the parental enzyme ß-lactamase TEM-1 to investigate different specific IgYs 
strategies to inhibit the growth of TEM-1 producing E.coli.  
This research included a bioinformatic analysis of the TEM-1 structure in the context of TEM-
derivative ESBLs. Then, two IgY strategies were designed to target the ß-lactamase TEM-1-producing 
E.coli (BW25113 ΔbamBΔtolC) with IgYs: as a complement to antibiotics (IgYs against the enzyme TEM-
1 used in combination with ampicillin) and as an alternative to antibiotics (IgYs against the bacteria 
TEM-1-producing E.coli without the addition of ampicillin). A good inhibitory effect of (a)TIgY, (a)p2IgY 
(in the presence of ampicillin) and eIgY, hIgY (without the ampicillin) on TEM-1-producing E.coli was 
observed in vitro. Moreover, they had the typical configuration of avian antibodies and were highly 
specific to their antigens. 
This study presents a model system to develop specific IgYs against a therapeutic target of 
interest. The activity of these IgYs complementary or alternatively to antibiotics should be further 
investigated in vivo in an animal infectious model. IgYs developed in this study might also be good 
candidates for further investigation as a broad-spectrum treatment against a variety of ESBL-producing 
E.coli. The aTIgY which was developed against the whole TEM-1 might also target its derivatives, as 
they have similar 3D structure with single amino acids mutations in the sequence. The ap2IgY was 
generated against catalytic and conservative residues, characteristic for the whole class A of ß-
lactamases, thus it might target also the active site of ESBL-s from this class. The strategy used to 
generate eIgY and hIgY was efficient and IgYs could be generated directly against ESBL-producing 
bacteria.   
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